Introduction {#s1}
============

The set of proteins expressed by a cell defines much of its potential capacities. However, a diverse set of modifications can occur after the protein is produced to alter its function and thus determine the cell's final behavior. One of the most frequent and variable of such alterations is glycosylation, in which sugars are added onto the oxygen (O) of a serine or threonine or onto the nitrogen (N) of an asparagine ([@bib69]; [@bib83]; [@bib94]). O-linked addition can occur on cytoplasmic and nuclear proteins in eukaryotes ([@bib31]; [@bib48]), but the most extensive N- and O- linked glycosylation occurs during the transit of a protein through the secretory pathway. A series of sugar molecules are added starting in the endoplasmic reticulum (ER) or cis-Golgi and continuing to be incorporated and removed until passage through the trans Golgi network is complete ([@bib1]; [@bib127]). N-linked glycosylation is initiated in the ER at consensus NxS/T X≠P site, whereas the most common GalNAc-type O-linked glycosylation is initiated in the early Golgi and glycosites display no clear sequence motifs, apart from a prevalence of neighboring prolines ([@bib13]; [@bib135]). Glycosylation can affect protein folding, stability and localization as well as serve specific roles in fine-tuning protein processing and functions such as protein adhesion and signaling ([@bib44]; [@bib142]). The basic process by which such glycosylation occurs has been well studied. However our understanding of how specific glycan structures participate in modulating particular cellular functions is still at its beginning.

The need to understand the regulation of O-glycosylation is particularly relevant for cancer ([@bib38]; [@bib50]). The truncated O-glycans called T and Tn antigen are not normally found on most mature human cells ([@bib22]) but up to 95% of cells from many cancer types display these at high levels ([@bib16]; [@bib22]; [@bib57]; [@bib78]; [@bib96]; [@bib124]; [@bib123]). The T O-glycan structure (Galβ1-3GalNAcα1-O-Ser/Thr) is synthesized by the large family of polypeptide GalNAc-transferases (GalNAc-Ts) that initiate protein O-glycosylation by adding GalNAc to form Tn antigen and the core1 synthase C1GalT1 that adds Gal to the initial GalNAc residues ([@bib137]) to form T antigen ([Figure 1A](#fig1){ref-type="fig"}). The human C1GalT1 synthase requires a dedicated chaperone, COSMC, for folding and ER exit ([@bib64]). In adult humans these O-glycans are normally capped by sialic acids and/or elongated and branched into complex structures ([@bib132]). However, in cancer this elongation and branching is reduced or absent and the appearance of these truncated T and Tn O-glycans correlates positively with cancer aggressiveness and negatively with long-term prognoses for many cancers in patients ([@bib9]; [@bib24]; [@bib36]; [@bib81]; [@bib112]; [@bib126]; [@bib125]; [@bib131]; [@bib151]). The molecular basis for the enhanced appearance of T antigen in cancers is not clear ([@bib28]), although higher Golgi pH in cancer cells correlates with increases in T antigen ([@bib67]). Interestingly, T antigen is also observed as a transient fetal modification ([@bib11]) and cancer cells frequently recapitulate processes that happened earlier in development ([@bib30]; [@bib102]). Identifying new mechanisms that regulate T antigen modifications developmentally has the potential to lead to insights into cancer biology.

![T antigen is enriched on *Drosophila* macrophages prior to and during their invasion of the extended germband.\
(**A**) Schematic of T antigen modification of serine (**S**) and threonine (**T**) on proteins within the Golgi lumen, through successive addition of GalNAc (yellow) by GalNAcTs and Gal (blue) by C1GalTs. Ugalt transports Gal into the Golgi. Glycosylation is shown at a much larger scale than the protein. (**B**) Schematic of an early Stage 12 embryo and a magnification of macrophages (red) entering between the germband ectoderm (dark grey), and mesoderm (light grey). (**C**) Schematic showing macrophages (red) disseminating from the head mesoderm in Stage 9. By Stage 10, they migrate towards the extended germband, the dorsal vessel and along the ventral nerve cord (vnc). At late Stage 11 germband invasion (arrow) begins and continues during germband retraction. Arrowhead highlights migration along the vnc in late Stage 12. (**D**) Table summarizing a screen of glycosylation-binding lectins for staining on macrophages invading the germband in late Stage 11 embryos. The listed binding preferences are abbreviated summaries of the specificities defined with mammalian glycans or simple saccharides which may have only incomplete relevance to insect glycomes. Enrichment was seen for PNA which recognizes T antigen and UEA-I which can recognize fucose. (**E**) Quantification of T antigen fluorescence intensities on wild type embryos shows upregulation on macrophages between Stage 9/10 and Stage 11/12. Arbitrary units (au) normalized to one for Stage 11. p\<0.0001. (**F--H**) Confocal images of fixed lateral wild type embryos from (**F**) Stage 9 and (**G--H**) early Stage 12 with T antigen visualized by antibody staining (green) and macrophages by *srpHemo-3xmCherry* expression (red). Schematics at left with black boxes showing the imaged regions. (**I**) Quantification of control shows T antigen enrichment on macrophages when normalized to whole embryo. RNAi in macrophages against C1GalTA by *srpHemo(macrophage)\>C1 GalTA RNAi vdrc2826* significantly decreases this T antigen staining (n = 8 embryos, p=0.011). (**J**) Representative confocal images of Stage 12 embryos from control and the aforementioned C1GalTA RNAi. Macrophages marked with cytoplasmic GFP (red) and nuclear RFP (green). (**K,L**) Quantification of macrophages in the germband in Stage 12 embryos for (**K**) control and two independent RNAis against C1GalTA (*vdrc110406 or vdrc2826*) expressed in macrophages by the *srpHemo-Gal4* driver (n = 21--31 embryos, p\<0.0001 and 0.017) or (**L**) in control and the *C1GalTA\[2.1\]* excision mutant (n = 23--24, p=0.0006). Macrophages labeled with *srpHemo-H2A::3xmCherry.* The RNAis and the mutant significantly decreased the macrophage number, arguing that T antigen is required in macrophages for germband entry. (**M**) Quantification of germband macrophages in early Stage 12 embryos in control and *GlcAT-P^MI05251^* embryos shows no defect in macrophage invasion in the mutant (n = 17--20, p=0.962). (**E**) analyzed by Kruskal-Wallis test **I, K-M** analyzed by Student's t-test. ns = p \> 0.05, \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001. Scale bars represent 10 μm in **F--H,** and 50 μm in **J**. See also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.\
10.7554/eLife.41801.005Figure 1---source data 1.Source data on the quantification of T antigen levels shown in [Figure 1E](#fig1){ref-type="fig"} and [Figure 1I](#fig1){ref-type="fig"}, the number of macrophages in the germband shown in [Figure 1K--M](#fig1){ref-type="fig"}, and the number on the yolk shown in [Figure 1---figure supplement 1N--O,Q](#fig1s1){ref-type="fig"} and on the vnc ([Figure 1---figure supplement 1P](#fig1s1){ref-type="fig"}).](elife-41801-fig1){#fig1}

*Drosophila* as a classic genetic model system is an excellent organism in which to investigate these questions. *Drosophila* displays T antigen as the predominant form of GalNAc-, or mucin-type, O-glycosylation in the embryo with 18% of the T glycans being further elaborated, predominantly by the addition of GlcA ([@bib4]). As in vertebrates, the GalNAc-T isoenzymes directing the initial step of GalNAc addition to serines and threonines are numerous in *Drosophila*, with several already known to display conserved substrate specificity *in vitro* with their vertebrate orthologs ([@bib89]; [@bib115]; [@bib133]). The *Drosophila* GalNAc-Ts affect extracellular matrix (ECM) secretion, gut acidification and the formation of the respiratory system ([@bib136]; [@bib141]; [@bib152]). In flies the main enzyme adding Gal to form T antigen is C1GalTA ([@bib89]) whose absence causes defects in ventral nerve cord (vnc) condensation during Stage 17, hematopoetic stem cell maintenance, and neuromuscular junction formation ([@bib39]; [@bib62]; [@bib79]; [@bib150]). While orthologous to the vertebrate Core1 synthases, the *Drosophil*a C1GALTs differ in not requiring a specific chaperone ([@bib89]). Most interestingly, T antigen is found on embryonic macrophages ([@bib150]), a cell type which can penetrate into tissues in a manner akin to metastatic cancer ([@bib105]; [@bib121]). Macrophage invasion of the germband ([Figure 1B](#fig1){ref-type="fig"}, arrow in [Figure 1C](#fig1){ref-type="fig"}) occurs between the closely apposed ectoderm and mesoderm ([@bib105]; [@bib121]) from late Stage 11 through Stage 12. This invasion occurs as part of the dispersal of macrophages throughout the embryo ([Figure 1C](#fig1){ref-type="fig"}) along other routes that are mostly noninvasive, such as along the inner ventral nerve cord (vnc) (arrowhead in [Figure 1C](#fig1){ref-type="fig"}) ([@bib21]; [@bib34]). Given these potentially related but previously unconsolidated observations, we sought to determine the relationship between the appearance of T antigen and macrophage invasion and to use the genetic power of *Drosophila* to find new pathways by which this glycophenotype is regulated.

Results {#s2}
=======

T antigen is enriched and required in invading macrophages in *Drosophila* embryos {#s2-1}
----------------------------------------------------------------------------------

To identify glycan structures present on fly embryonic macrophages during invasion we performed a screen examining FITC-labelled lectins (see Materials and methods for abbreviations). Only two lectins had higher staining on macrophages than on surrounding tissues (labeled enriched): PNA, which primarily binds to the core1 T O-glycan, and UEA-I, which can recognize Fucα1-2Galβ1-4GlcNAc([@bib87]; [@bib90]) ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A--B](#fig1s1){ref-type="fig"}). Both glycans are associated with the invasive migration of mammalian cancer cells ([@bib2]; [@bib60]). SBA, WGA, GS-II, GS-I, ConA, MPA and BPA bound at similar or lower levels on *Drosophila* macrophages compared to flanking tissues ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C--I](#fig1s1){ref-type="fig"}). We saw no staining with the sialic acid-recognizing lectin LPA, and none with DBA and HPA, that both recognize α-GalNAc ([@bib103]) ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1J--L](#fig1s1){ref-type="fig"}). Thus PNA and UEA-I display enriched macrophage binding during their embryonic invasive migration.

To confirm T antigen as the source of the upregulated PNA signal in embryonic macrophages during invasion and to characterize its temporal and spatial enrichment, we used a monoclonal antibody (mAb 3C9) to the T O-glycan structure ([@bib128]). Through Stage 10, macrophages displayed very little T antigen staining, similar to other tissues ([Figure 1E,F](#fig1){ref-type="fig"}). However, at late Stage 11 ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) and early Stage 12, when macrophages start to invade the extended germband, T antigen staining began to be enriched on macrophages moving towards and into the germband ([Figure 1E--H](#fig1){ref-type="fig"}). Our results are consistent with findings showing T antigen expression in a macrophage-like pattern in late Stage 12 embryos, and on a subset of macrophages at Stage 16 ([@bib150]). We knocked down the core1 synthase C1GalTA required for the final step of T antigen synthesis ([Figure 1A](#fig1){ref-type="fig"}) ([@bib79]; [@bib89]) using RNAi expression only in macrophages and observed strongly reduced staining ([Figure 1I](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1M](#fig1s1){ref-type="fig"}). We conclude that the antibody staining is the result of T antigen produced by macrophages themselves.

To determine if these T O-glycans on macrophages are important for facilitating their germband invasion, we knocked down C1GalTA in macrophages with the RNAi line utilized above as well as one other and used the P element excision allele *C1GalTA\[2.1\]* which removes conserved sequence motifs required for activity ([@bib79]). We visualized macrophages through specific expression of fluorescent markers and observed a 25 and a 33% decrease in their number in the germband for the RNAis ([Figure 1J,K](#fig1){ref-type="fig"}), and a 44% decrease in the C1GalTA\[2.1\] mutant ([Figure 1L](#fig1){ref-type="fig"}). When we counted the number of macrophages sitting on the yolk next to the germband in the strongest RNAi we observed an increase ([Figure 1---figure supplement 1N](#fig1s1){ref-type="fig"}) that we also observed in the C1GalT mutant ([Figure 1---figure supplement 1O](#fig1s1){ref-type="fig"}). The sum of the macrophages in the yolk and germband is the same in the control, RNAi knockdown (control 136.5 ± 6.4, RNAi 142.3 ± 6.6, p=0.7) and mutant (control 138.5 ± 4.9, mutant, 142.3 ± 7.4, p=0.87) arguing that macrophages in which C1GalTA levels are reduced cannot enter the germband but are retained on the yolk. We observed no effect on the migration of macrophages on the vnc, a route that does not require tissue invasion ([Figure 1---figure supplement 1P](#fig1s1){ref-type="fig"}) ([@bib21]; [@bib34]). 18% of T antigen in the embryo has been found to be further modified, predominantly by glucuronic acid (GlcA) ([@bib4]). Of the three GlcA transferases found in *Drosophila* only GlcAT-P is robustly capable of adding GlcA onto the T O-glycan structure in cells ([@bib18]; [@bib63]; [@bib68]). To examine if the specific defect in germband invasion that we observed by blocking the formation of T antigen is due to the need for a further elaboration by GlcA, we utilized a lethal MI{MIC} transposon insertion mutant in the *GlcAT-P* gene. We observed no change in the numbers of macrophages within the germband in the *GlcAT-P^MI05251^* mutant ([Figure 1M](#fig1){ref-type="fig"}) and a 20% increase in the number of macrophages on the yolk ([Figure 1---figure supplement 1Q](#fig1s1){ref-type="fig"}). Therefore, our results strongly suggest that the T antigen we observe being upregulated in macrophages as they move towards and into the germband is itself needed for efficient tissue invasion.

An atypical MFS member acts in macrophages to increase T antigen levels {#s2-2}
-----------------------------------------------------------------------

We sought to determine which proteins could temporally regulate the increase in the appearance of T O-glycans in invading macrophages. We first considered proteins required for synthesizing the core1 structure, namely the T synthase, C1GalTA, and the UDP-Gal sugar transporter, Ugalt ([@bib7]) ([Figure 1A](#fig1){ref-type="fig"}). However, q-PCR analysis of FACS sorted macrophages from Stage 9--10, Stage 12, and Stage 13--17 show that though both are enriched in macrophages, neither is transcriptionally upregulated before or during Stage 12 ([Figure 2A,B](#fig2){ref-type="fig"}). We therefore examined the Bloomington *Drosophila* Genome Project (BDGP) in situ database looking for predicted sugar binding proteins expressed in macrophages with similar timing to the observed T antigen increase ([@bib140]; [@bib139]). We identified CG8602, a predicted member of the Major Facilitator Superfamily (MFS), a protein group defined by shared structural features, whose members are known to transport a diverse set of molecules across membranes ([@bib148]). CG8602 contains regions of homology to known sugar responsive proteins and predicted sugar or neurotransmitter transporters ([Figure 2C](#fig2){ref-type="fig"}) and in a phylogenetic analysis is on a branch neighboring the SLC29 group shown to be involved in nucleoside transport ([@bib10]; [@bib100]). BDGP in situ hybridizations ([@bib140]; [@bib139]) (<http://insitu.fruitfly.org/cgi-bin/ex/report.pl?ftype=10&ftext=FBgn0035763>) indicate that CG8602 RNA is maternally deposited, with expression throughout the embryo through Stage 4 after which its levels decrease, with weak ubiquitous expression continuing through Stage 9--10. This is followed by strong enrichment in macrophages from Stage 11--12, with apparently equivalent levels of expression in macrophages entering the germband as in those migrating along other routes such as the ventral nerve cord. We confirmed this by q-PCR analysis of FACS sorted macrophages, which detected seven-fold higher levels of CG8602 RNA in macrophages than in the rest of the embryo by Stage 9--10 and 12-fold by Stage 12 ([Figure 2D](#fig2){ref-type="fig"}). These data show that RNA expression of CG8602, an MFS protein with homology to sugar transporters, increases in macrophages preceding and during the period of invasion.

![An atypical MFS family member, CG8602, located in the Golgi and endosomes, is required for T antigen enrichment on invading macrophages.\
(**A,B**) qPCR quantification (2^-ΔCt^) of RNA levels in *mCherry+* macrophages FACS sorted from *srpHemo-3xmCherry* wild type embryos reveals no significant change in the expression of (**A**) the C1GalTA galactose transferase or (**B**) the Ugalt Gal transporter during Stage 9--17 (n = 7 biological replicates, three independent FACS sorts). (**C**) Schematic made with Protter ([@bib95]) showing the predicted 12 transmembrane domains of CG8602. Blue lines indicate regions displaying higher than 20% identity to the correspondingly numbered *Drosophila* protein indicated below, along with the homologous protein's predicted or determined function. (**D**) Quantification by qPCR of CG8602 RNA levels in FACS sorted *mCherry+* macrophages compared to other *mCherry-* cells obtained from *srpHemo-3xmCherry* wild type embryos at Stage 9--10, Stage 12 and Stage 13--17. CG8602 macrophage expression peaks at Stage 12, during macrophage germband entry (n = 3--7 biological replicates, four independent FACS sorts, p=0.036). (**E**) qPCR quantification in FACS sorted *srpHemo-3xmCherry* labeled macrophages from control and *CG8602^EP3102^* mutant Stage 12 embryos shows an extremely strong decrease in CG8602 RNA expression in the P element insertion mutant used in this study (n = 7 biological replicates, three independent FACS sorts, p=0.0024). (**F**) Confocal images of Stage 12 control and *CG8602^EP3102^* mutant embryos with macrophages (red) visualized by *srpHemo-mCherry* expression and T antigen by antibody staining (green). Schematic at left depicts macrophages (red) entering the germband. Black box indicates the region next to the germband imaged at right. We observe decreased T antigen staining on macrophages in the *CG8602^EP3102^* mutant compared to the control. (**G**) qPCR quantification (2^-ΔCt^) of C1GalTA and Ugalt RNA levels in FACS sorted macrophages from Stage 12 embryos from control and *CG8602^EP3102^* mutant embryos shows no significant change in expression of the Gal transferase, or the Gal and GalNAc transporter in the mutant compared to the control (n = 7 biological replicates, three independent FACS sorts). (**H**) Quantitation using Fiji of the colocalization of transfected *MT-CG8602::FLAG::HA* in fixed S2R+ cells with markers for the ER (Cnx99a), the Golgi (Golgin 84, Golgin 245, and GMAP), the early endosome (Hrs), the late endosome (Rab7), and live S2R+ cells transfected with *srp-CG8602::3xmCherry* with dyes that mark the lysosome (Lysotracker) and the nucleus (DAPI). Representative images are shown in [Figure 2---figure supplement 1 B-J](#fig2s1){ref-type="fig"}. n = 24, 23, 23, 17, 6, 22, 6 and 13 cells analyzed per respective marker. (**I**) Macrophages near the germband extracted from *srpHemo \>CG8602* HA Stage 11/12 embryos show partial colocalization of the HA antibody labeling CG8602 (red) and a Golgin 84 or Hrs antibody marking the Golgi or endosome respectively (green). Nucleus is stained by DAPI (blue). For all qPCR experiments values are normalized to expression of a housekeeping gene RpL32. Scale bars are 5 μm in **F,** 3 μm in **I**. Significance was assessed by Kruskal-Wallis test in **A, B**, One way Anova in **D** and Student's t-test in **E, G**. ns = p \> 0.05, \*p\<0.05, \*\*\*p\<0.001. See also [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}.\
10.7554/eLife.41801.008Figure 2---source data 1.Source data on the quantification of C1GalTA, Ugalt, and CG8602 expression in macrophages by qPCR (shown in [Figure 2A--B,D--E,G](#fig2){ref-type="fig"}) and the Pearson's coefficient for CG8602 colocalization with different markers ([Figure 2H](#fig2){ref-type="fig"}).](elife-41801-fig2){#fig2}

To determine if CG8602 could affect T antigen levels, we examined a viable P-element insertion mutant in the 5'UTR, *CG8602^EP3102^* ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). This insertion displays strongly reduced CG8602 expression in FACS-sorted macrophages to 15% of wild type levels, as assessed by q-PCR ([Figure 2E](#fig2){ref-type="fig"}). We also created an excision allele, ∆33, removing the 5'UTR flanking the P-element, the start methionine, and 914 bp of the ORF ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). This is a lethal allele, and the line carrying it over a balancer is very weak; exceedingly few embryos are laid and the embryos homozygous for the mutation do not develop past Stage 12. Therefore, we did not continue experiments with this allele, and instead utilized the insertion mutant. This *CG8602^EP3102^* P-element mutant displays decreased T antigen staining on macrophages moving toward and entering the germband ([Figure 2F](#fig2){ref-type="fig"}) in Stage 11 through late Stage 12. q-PCR analysis on FACS sorted macrophages show that the reduction in T antigen levels in the mutant is not caused by changes in the RNA levels of the T synthase C1GalTA or the Ugalt Gal and GalNAc transporter ([@bib7]; [@bib117]) ([Figure 2G](#fig2){ref-type="fig"}). These results argue that CG8602 is required for enriched T antigen levels on macrophages.

To assess if CG8602 could directly regulate T antigen addition, we examined if it is found in the Golgi where O-glycosylation is initiated. We first utilized the macrophage-like S2R+ cell line, transfecting a FLAG::HA or 3xmCherry labeled form of CG8602 under the control of *srpHemo* or the copper inducible MT promoter. We detected significant colocalization with markers for the cis-Golgi marker GMAP, the Trans Golgi Network marker Golgin 245 and the endosome markers Rab7, Rab11 and Hrs ([@bib108]) ([Figure 2H](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1C--G](#fig2s1){ref-type="fig"}). We detected no colocalization with markers for the nucleus, ER, peroxisomes, mitochondria or lysosomes ([Figure 2H](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1B,H--J](#fig2s1){ref-type="fig"}). We confirmed the presence of CG8602 in the Golgi and endosomes in macrophages from late Stage 11 embryos through colocalization with Golgin 84 and Hrs, using cells extracted from positions in the head adjacent to the germband ([Figure 2I](#fig2){ref-type="fig"}). We conclude that the T antigen enrichment on macrophages migrating towards and into the germband requires a previously uncharacterized atypical MFS with homology to sugar binding proteins that is localized predominantly to the Golgi and endosomes.

The MFS, Minerva, is required in macrophages for dissemination and germband invasion {#s2-3}
------------------------------------------------------------------------------------

We examined if CG8602 affects macrophage invasive migration. The *CG8602^EP3102^* mutant displayed a 35% reduction in macrophages within the germband at early Stage 12 compared to the control ([Figure 3A--B,D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). The same decrease is observed when the mutant is placed over the deficiency Df(3L)BSC117 that removes the gene entirely ([Figure 3D](#fig3){ref-type="fig"}), arguing that *CG8602^EP3102^* is a genetic null for macrophage germband invasion. The P element transposon insertion itself causes the migration defect because its precise excision restored the number of macrophages in the germband to wild type levels ([Figure 3D](#fig3){ref-type="fig"}). Expression of the CG8602 gene in macrophages can rescue the *CG8602^EP3102^* P element mutant ([Figure 3C--D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}), and RNAi knockdown of CG8602 in macrophages can recapitulate the mutant phenotype ([Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Our data thus argue that CG8602 is required in macrophages themselves for germband invasion.

![CG8602, which we name Minerva, is required in macrophages for their efficient invasion of the germband.\
(**A--C**) Representative confocal images of early Stage 12 embryos from (**A**) control, (**B**) *P{EP}CG8602^EP3102^ = minerva (mrva)^3102^* mutant, and (**C**) *mrva^3102^* mutants with macrophage expression of the gene rescued by *srpHemo(macro)-mrva. *Macrophages express *srpHemo-3XmCherry* (red) and the embryo autofluoresces (green). In the mutant, macrophages remain in the head and fail to enter the germband, hence we name the gene *minerva*. (**D**) Dashed ellipse in schematic at left represents the germband region in which macrophages (red) were counted throughout the study. Comparison of the control (n= 38), *mrva^3102^* mutants (n = 37) and *mrva^3102^* mutant/Df(3L)BSC117 that removes the gene (n = 23) shows that the mutant significantly decreases migration into the extended germband (p\<0.0001 for control vs mutant, p=-0002 for control vs Df cross). This defect can be partially rescued by expression in macrophages of *srpHemo \>mrva::FLAG::HA* (n = 18, p=0.222 for control vs rescue, p=0.036 for mutant vs rescue) and completely rescued by precise excision (*mrva^Δ32^*) of the P element (n = 16, p=0.826). *srpHemo \>mCherry* nls labeled the macrophages. (**E--G**) Macrophage quantification in early Stage 12 embryos. (**E**) Fewer germband macrophages upon expression of *mrva* RNAi *[v101575](https://stockcenter.vdrc.at/control/product/~VIEW_INDEX=0/~VIEW_SIZE=100/~product_id=101575)* only in macrophages under the control of *srpHemo* (n = 28--35 embryos, p\<0.0001). (**F**) Fewer macrophages found on the yolk neighboring the germband (oval in schematic) in the *mrva^3102^* mutant compared to control embryos (n = 14--16 embryos, p=0.0003). (**G**) Increased germband macrophage numbers in *shg^P34^; mrva^3102^* compared to the *mrva^3102^* mutant indicates a partial rescue from reducing DE-Cadherin which is expressed in the germband ectoderm (n = 19--29, p\<0.0001, p=0.005). (**H**) No significant difference in number of macrophages labeled with *srpHemo-3xmCherry* in vnc segments (area in blue oval in schematic) between control and *mrva^3102^* mutant embryos in fixed mid Stage 12 embryos (n = 23--25, p=0.55). Images from two-photon movies of (**I**) Stage 10 and (**L**) late Stage 11-early Stage 12 embryos in which macrophage nuclei (red) are labeled with *srpHemo-H2A::3xmCherry*. (**I**) Stills at 0 and 60 min and (**J**) quantification of macrophage speed reveal 33% slower macrophage migration in the head towards the yolk neighboring the germband in the *mrva^3102^* mutant compared to the control, n = 3 movies for each, \#tracks: control = 329, mutant = 340, p=0.002. Blue box in magnification in schematic indicates region analysed in J. (**K**) The first macrophage in *mrva^3102^* mutants is much slower to enter the germband after macrophages reach the germband edge (control = 22.00 ± 1.53 min, n = 3, *mrva^3102^* mutant = 102.0 ± 20.35 min, n = 4. p-value=0.021). (**L**) The time when macrophages reached the germband in each genotype was defined as 0'. Stills at 60 and 90 min and (**M**) quantification of macrophage speed reveal 43% slower macrophage migration in the germband in the *mrva^3102^* mutant compared to the control. Blue arrow in schematic indicates route analyzed. n = 3 movies for each, \#tracks: control = 21, mutant = 14, p=0.022. Significance was assessed by Kruskal-Wallis test with Conover post test comparison in D, G, Student's t-test in E, F, H, J-K, M. ns = p \> 0.05, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*p\<0.0001. Scale bars are 50 μm in A-C, 40 μm in I, 30 μm in L. See also [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---video 1](#fig3video1){ref-type="video"}--[3.](#fig3video3){ref-type="video"}\
10.7554/eLife.41801.011Figure 3---source data 1.Source data on the quantification of macrophages in the germband shown in [Figure 3D--E,G](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}, on the yolk ([Figure 3F](#fig3){ref-type="fig"}) on the vnc ([Figure 3H](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}) and in the whole embryo ([Figure 3---figure supplement 1D--E](#fig3s1){ref-type="fig"}).Source data on the xyz position of macrophages from the tracks that form the basis of the analysis shown in [Figure 3J--K,M](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1F,G](#fig3s1){ref-type="fig"}. Source data on the mismigration of germ cells, the levels of mrva expression in the ovary, and the migration of border cells ([Figure 3---figure supplement 1I,J and L](#fig3s1){ref-type="fig"}, respectively). Source data on the xyz position of macrophages in the movies of the *mrva^3102^* mutant and the control underlying the analysis shown in [Figure 3J-K,M](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1F-G](#fig3s1){ref-type="fig"}.](elife-41801-fig3){#fig3}

Decreased numbers of macrophages in the extended germband could be caused by specific problems entering this region, or by general migratory defects or a decreased total number of macrophages. To examine the migratory step that precedes germband entry, we counted the number of macrophages sitting on the yolk next to the germband in fixed embryos in the *CG8602^EP3102^* mutant. We observed a 30% decrease compared to the control ([Figure 3F](#fig3){ref-type="fig"}), suggesting a defect in early dissemination. Entry into the germband by macrophages occurs between the closely apposed DE-Cadherin expressing ectoderm and the mesoderm and is accompanied by deformation of the ectodermal cells ([@bib105]). We tested if reductions in DE-Cadherin could ameliorate the germband phenotype. Indeed, combining the *CG8602^EP3102^* mutation with *shg^P34^* which reduces DE-Cadherin expression ([@bib98]; [@bib134]) produced a partial rescue ([Figure 3G](#fig3){ref-type="fig"}), consistent with CG8602 playing a role in germband entry as well as in an earlier migratory step. There was no significant difference in the number of macrophages migrating along the vnc in late Stage 12 compared to the control in fixed embryos ([Figure 3H](#fig3){ref-type="fig"}) from the *CG8602^EP3102^* mutant or from a knockdown in macrophages of *CG8602* by RNAi ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}), arguing against a general migratory defect. There was also no significant difference in the total number of macrophages in either case ([Figure 3---figure supplement 1D--E](#fig3s1){ref-type="fig"}). From analyzing the *CG8602* mutant phenotype in fixed embryos we conclude that CG8602 does not affect later vnc migration but is important for the early steps of dissemination and germband invasion.

To examine the effect of CG8602 on macrophage speed and dynamics, we performed live imaging of macrophages labeled with the nuclear marker *srpHemo-H2A::3xmCherry* in control and *CG8602^EP3102^* mutant embryos ([Figure 3---video 1](#fig3video1){ref-type="video"} and [2](#fig3video2){ref-type="video"}). We first imaged macrophages migrating from their initial position in the delaminated mesoderm up to the germband and detected a 33% decrease in speed (2.46 ± 0.07 μm/min in the control, 1.66 ± 0.08 μm/min in the *CG8602^EP3102^* mutant, p=0.002) ([Figure 3I,J](#fig3){ref-type="fig"}) and no significant decrease in persistence (0.43 ± 0.02 in the control, 0.40 ± 0.01 in the mutant, p=0.22) ([Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}). We then examined the initial migration of macrophages into the germband at late Stage 11. We observed a range of phenotypes in the six movies we made of the mutant, with macrophages pausing at the germband edge from twice to six times as long as in the control before invading into the tissue ([Figure 3K](#fig3){ref-type="fig"} shows average time for entry, control = 22.00 ± 1.53 min, *CG8602^EP3102^* mutant = 102.0 ± 20.35 min). As we observed no change in the timing of the initiation of germband retraction (269.6 ± 9 min in control and 267.1 ± 3 min in mutant, p=0.75) but did observe a decreased speed of its completion in the mutant (107 ± 12 min from start to end of retraction in control and 133 ± 6 min for mutant p=0.05), we only analyzed macrophages within the germband before its retraction begins. We observed a 43% reduction in macrophage speed within the germband (2.72 ± 0.32 μm/min in the control and 1.55 ± 0.04 μm/min in the mutant, p=0.02) ([Figure 3L,M](#fig3){ref-type="fig"}). To assess this phenotype's specificity for invasion, we used live imaging of macrophage migration along the inner vnc that occurs during the same time period as germband entry; we observed no significant change in speed (2.41 ± 0.06 μm/min in the control and 2.23 ± 0.01 μm/min in the mutant, p=0.11) or directionality (0.43 ± 0.03 in the control and 0.43 ± 0.02 in the mutant, p=0.9742) ([Figure 3---figure supplement 1G](#fig3s1){ref-type="fig"}, [Figure 3---video 3](#fig3video3){ref-type="video"}). We conclude from the sum of our experiments in fixed and live embryos that CG8602 is important for the initial disseminatory migration out of the head and for invasive migration into and within the germband, but does not alter general migration. We name the gene *minerva (mrva)*, for the Roman goddess who was initially trapped in the head of her father, Jupiter, after he swallowed her pregnant mother who had turned herself into a fly.

Minerva is not required for border cell invasion or germ cell migration {#s2-4}
-----------------------------------------------------------------------

To assess if Minerva only affects macrophage invasion or also other types of tissue penetration in *Drosophila*, we examined the migration of germ cells and border cells. Germ cells move in an Integrin-independent fashion through gaps in the midgut created by ingressing formerly epithelial cells ([@bib32]; [@bib118]). We found no defect in germ cell migration when examining control and *mrva^3102^* mutant embryos stained with the Vasa Ab ([Figure 3---figure supplement 1H--I](#fig3s1){ref-type="fig"}). Border cells are born in the epithelia surrounding the ovary and then delaminate to move invasively between the nurse cells towards the oocyte ([@bib88]), guided by the same receptor that macrophages use during their embryonic dispersal, PVR ([@bib33]). They migrate as a tumbling collective, using invadopodia and Cadherin-based adhesion to progress ([@bib20]; [@bib91]). *mrva* is expressed in dissected control ovaries and the *mrva^3102^* mutant reduces the levels of *mrva* RNA in the ovary by 70%, similar to the reduction observed in macrophages ([Figure 3---figure supplement 1J](#fig3s1){ref-type="fig"}). We identified border cells by staining with DAPI to detect their clustered nuclei. We observed no significant change in border cell migration towards the oocyte in the *mrva^3102^* mutant compared to the control ([Figure 3---figure supplement 1K--L](#fig3s1){ref-type="fig"}). These results support the conclusion that Mrva is not generally required for all migratory cells that move confined through tissues during development, but specifically for the invasion of macrophages, which is an Integrin-dependent process ([@bib121]).

Minerva affects a small fraction of the *Drosophila* embryonic O-glycoproteome {#s2-5}
------------------------------------------------------------------------------

We set out to determine if Minerva induces T glycoforms on particular proteins. We first conducted a Western Blot with a mAb to T antigen on whole embryo extracts. We used the whole embryo because we were unable to obtain enough protein from FACS sorted macrophages or to isolate CRISPR-induced full knockouts of *minerva* in the S2R+ macrophage like cell line. We observed that several bands detected with the anti-T mAb were absent or reduced in the *minerva* mutant ([Figure 4A](#fig4){ref-type="fig"}), indicating an effect on the T antigen modification of a subset of proteins.

![Glycoproteomic analysis reveals Minerva is required for higher levels of T-antigen on a subset of proteins.\
(**A**) Representative Western blot of protein extracts from Stage 11/12 control and *mrva^3102^* mutant embryos probed with T antigen antibody. Arrows indicate decreased/missing bands in the mutant compared to the control. Profilin serves as a loading control (n = 10 biological replicates). (**B**) Summary of glycomics results on wild type embryos. (**C**) Venn diagram indicating number of glycosites or proteins found with T, Tn or T and Tn antigen modifications in the wild type. (**D**) Plot showing the number of T and Tn antigen glycosites per protein in the total glycoproteome and on proteins that show three (blue) and ten-fold (red) altered glycopeptides in the *mrva^3102^* mutant. Proteins strongly affected by Minerva have a higher number of glycosites (p=0.005). (**E**) Summary of glycomics on *mrva^3102^* embryos showing the numbers of proteins and glycosites exhibiting three (blue) or ten (red) fold changes in T and Tn antigen levels. (**F**) T antigen (in green) and Tn antigen (orange) occupied glycosites plotted against the ratio of the levels of glycopeptides found for each glycosite in the *mrva^3102 ^*mutant/control. Higher positions on the plot indicate a lower level of glycosylation in the mutant. Blue dashed line represents the cut off for 3x changes in glycosylation, and the red dotted line the 10x one. (**G**) Venn diagram of the number of proteins with at least three fold change in the T antigen (T, green) or Tn antigen (Tn, orange) glycosylation in the *mrva^3102^* mutant. Up arrows denote increase, down arrows indicate decrease in levels. (**H**) Proteins with at least a three fold decrease in T antigen levels in the *mrva^3102^* mutant. Glycan modified amino acids are highlighted in bold green font. Unchanged/Higher GS column indicates if any other glycosite on the protein is unchanged or increased. Table does not show the two chitin and chorion related genes unlikely to function in macrophages. G: Golgi, ES: Extracellular space, Endo: Endosomes, ER: Endoplasmic reticulum, ECM: Extracellular Matrix, PM: Plasma Membrane, GS: Glycosite. Cancer links as follows. 1) QSOX1: Promotes cancer invasion in vitro, overexpression worse patient outcomes ([@bib66]; [@bib65]). 2) HYOU1: Overexpression associated with vascular invasion, worse patient outcomes ([@bib130]) ([@bib154]). 3) TMEM87B: translocation breakpoint in cancer, ([@bib58]). 4) ACVR2B: over expressed in renal cancer ([@bib119]). 5) GANAB: inhibits cancer invasion in vitro ([@bib29]). 6) LRIG1: inhibits cancer invasion in vitro, and in mice ([@bib120]), ([@bib82]). (**I**) Annotated ETD MS2 spectra of the VHQPSATPASK glycopeptide from Qsox1 with T antigen glycosylation at position T7. See schematic in which the yellow square represents GalNAc and the yellow circle Gal. Assigned fragment ions in MS2 spectra are highlighted by red for 'c' type fragments (those retaining the original N terminus) and blue for 'z' type fragments (those retaining the original C terminus). The graph at the left shows the relative quantification of the glycopeptide precursor ion's peak area in the control and *mrva^3102^* mutant plotted on a logarithmic scale. See also [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}-Dataset 1, [Supplementary file 1](#supp1){ref-type="supplementary-material"}--[3](#supp3){ref-type="supplementary-material"}.](elife-41801-fig4){#fig4}

We wished to obtain a more comprehensive view of the proteins affected by Minerva. Since there is little information about *Drosophila* O-glycoproteins and O-glycosites ([@bib116]; [@bib5]), we used lectin-enriched O-glycoproteomics to identify proteins displaying T and Tn glycoforms in Stage 11/12 embryos from wild type and *mrva^3102^* mutants ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). We labeled tryptic digests of embryonic protein extracts from control or mutant embryos with stable dimethyl groups carrying medium (C~2~H~2~D~4~) or light (C~2~H~6~) isotopes respectively to allow each genotype to be identified in mixed samples ([@bib15]; [@bib113]; [@bib114]). The pooled extracts were passed over a Jacalin column to enrich for T and Tn O-glycopeptides; the eluate was analyzed by mass spectrometry to identify and quantify T and Tn modified glycopeptides in the wild type and the mutant sample through a comparison of the ratio of the light and medium isotope labeling channels for each glycopeptide (see [Figure 4---figure supplement 1B--C](#fig4s1){ref-type="fig"} for example spectra).

In the wild type we identified T and Tn glycopeptides at 936 glycosites derived from 270 proteins ([Supplementary file 1](#supp1){ref-type="supplementary-material"} and [Figure 4B](#fig4){ref-type="fig"}). 62% of the identified O-glycoproteins and 77% of identified glycosites contained only Tn O-glycans. 33% of the identified O-glycoproteins and 23% of glycosites displayed a mixture of T or Tn O-glycans, and 5% of identified O-glycoproteins and 4% of glycosites had solely T O-glycans ([Figure 4C](#fig4){ref-type="fig"}). In agreement with previous studies ([@bib129]), only one glycosite was found in most of the identified O-glycoproteins (44%) ([Figure 4D](#fig4){ref-type="fig"}). In 20% we found two sites, and some glycoproteins had up to 27 glycosites. The identified O-glycosites were mainly on threonine residues, (78.5%) with some on serines (21.2%) and very few on tyrosines (0.3%) ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}). Metabolism, cuticle development, and receptors were the most common functional assignments for the glycoproteins ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}).

We sought to assess the changes in glycosylation in the *mrva* mutant. A majority of the quantifiable Tn and T O-glycoproteome was unaltered between the wild type and the *mrva^3102^* mutant, with only 63 proteins (23%) showing more than a three-fold change and 18 (6%) a ten-fold shift ([Figure 4F](#fig4){ref-type="fig"}). We observed both increases and decreases in the levels of T and Tn modification on proteins in the mutant ([Figure 4F--G](#fig4){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}), but a greater number of proteins showed decreased rather than increased T antigen levels. 67% of the vertebrate orthologs of *Drosophila* proteins displaying shifts in this O-glycosylation have previously been linked to cancer ([Figure 4H](#fig4){ref-type="fig"}, [Supplementary file 2](#supp2){ref-type="supplementary-material"}). These proteins were affected at specific sites, with 40% of glycosites on these proteins changed more than three fold and only 14% more than ten fold. The glycosite shifts in T antigen occurred either without significant alterations in Tn (33% of glycosites had only decreased T antigen, 17% of glycosites had only increased T antigen) or with changes in T antigen occurring in the same direction as the changes in Tn (22% of glycosites both Tn and T antigen increased, 22% of glycosites both Tn and T decreased) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Only 1% of glycosites displayed decreased T antigen with a significant increase in Tn. Interestingly, a higher proportion of the glycoproteins with altered O-glycosylation in the *mrva^3102^* mutant had multiple glycosites than the general glycoproteome ([Figure 4D](#fig4){ref-type="fig"}) (p value=0.005 for ten-fold changes). We conclude that Minerva affects O-glycosylation occupancy on a small subset of O-glycoproteins, many of whose vertebrate orthologs have been linked to cancer, with both T and Tn O-glycopeptides being affected.

Minerva raises T antigen levels on proteins required for invasion {#s2-6}
-----------------------------------------------------------------

Given that blocking Tn to T conversion through the knockdown of the C1GalTA enzyme resulted in a germband invasion defect, we examined the known functions of the 18 proteins with lower T antigen in the absence of Minerva to distinguish which processes Minerva could influence to facilitate invasion ([Figure 4H](#fig4){ref-type="fig"}). We excluded two proteins involved in eggshell and cuticle production. To spot proteins whose reduced T antigen-containing glycopeptides are caused directly by alterations in glycosylation rather than indirectly by decreased protein expression in the *mrva* mutant, we checked if glycosylation at other identified glycosites was unchanged or increased. We identified ten such proteins, several of which were in pathways that had been previously linked to invasion in vertebrates. Qsox1, a predicted sulfhydryl oxidase required for the secretion and thus potential folding of EGF repeats ([@bib138]) showed the strongest alterations of any protein, with a 50-fold decrease in T antigen levels in the *mrva* mutant ([Figure 4I](#fig4){ref-type="fig"}). The mammalian ortholog QSOX1 has been shown to affect disulfide bond formation, is overexpressed in some cancers, promotes Matrigel invasion, and can serve as a negative prognostic indicator in human cancer patients ([@bib26]; [@bib65]; [@bib72]). Dtg, with a 13-fold reduction in T antigen ([@bib54]), and Put with a five-fold reduction ([@bib73]) respond to signaling by the BMP-like ligand, Dpp. Dpp signaling directs histoblast invasion in the fly ([@bib92]). Gp150 shows a four fold decrease in T antigen and modulates Notch signaling ([@bib37]; [@bib76]). Notch and BMP promote invasion and metastasis in mice ([@bib8]; [@bib40]; [@bib97]; [@bib101]; [@bib110]; [@bib122]). We conclude that Mrva is required to increase T O-glycans on a subset of the glycosites of selected glycoproteins involved in protein folding, glycosylation and signaling in pathways frequently linked to promoting cancer metastasis. Its strongest effect is on a predicted sulfhydryl oxidase, the *Drosophila* ortholog of the mammalian cancer protein, QSOX1.

We wished to determine how Qsox1 might affect *Drosophila* macrophage germband invasion. Embryos from the KG04615 P element insertion in the 5'UTR of the *qsox1* gene displayed 42% fewer macrophages in the germband compared to the control ([Figure 5A,B](#fig5){ref-type="fig"}) with an increase in macrophages remaining on the yolk ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). We observed a small decrease in migration along the vnc ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}) and no change in total macrophage numbers in these embryos ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). These migration phenotypes were also observed in embryos in which RNAi line v108288 knocked down *qsox1* only in macrophages ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1D--E](#fig5s1){ref-type="fig"}). We then conducted live imaging ([Figure 5D](#fig5){ref-type="fig"}, [Figure 5---video 1](#fig5video1){ref-type="video"}) (compare to control shown in [Figure 3---video 1](#fig3video1){ref-type="video"}) to examine how the *qsox1^KG04615^* mutant affected the dynamics of macrophage migration. During the movement of macrophages labeled with the nuclear marker *srpHemo-H2A::3xmCherry* from their initial position up to the germband we detected an 18% decrease in speed ([Figure 5E](#fig5){ref-type="fig"}) (2.46 ± 0.07 μm/min in the control, 2.02 ± 0.03 μm/min in the *qsox1^KG046152^* mutant, p=0.006, n = 3) and no significant decrease in persistence ([Figure 5---figure supplement 1F](#fig5s1){ref-type="fig"}) (0.43 ± 0.02 in the control, 0.39 ± 0.01 in the mutant, p=0.13). Macrophages in the *qsox1* mutant were delayed twice as long at the germband edge before entering ([Figure 5F](#fig5){ref-type="fig"}) (time to entry 22.00 ± 1.53 min in the control and 49.67 ± 9.33 min in the *qsox1^KG046152^* mutant, n = 3). Once in, they moved within the germband with a 17% slower speed, a reduction that was not statistically significant ([Figure 5G](#fig5){ref-type="fig"}) (2.72 ± 0.32 μm/min in the control, 2.27 ± 0.20 μm/min in the *qsox1^KG046152^* mutant, p=0.30, n = 3). We conclude that Qsox1 aids the disseminatory migration of macrophages but is most strongly required for their initial invasion into the germband tissues.

![Qsox1 is required for macrophage dissemination and entry into the germband tissue.\
(**A**) Representative confocal images of early Stage 12 embryos from control and *P{SUPor-P}Qsox1KG04615* = *qsox1*^*KG04615*^. (**B--C**) Quantification in early Stage 12 embryos showing a significant reduction in germband macrophages (**B**) in the P-element mutant *qsox1^KG04615^* located in the Qsox1 5'UTR (n = 18, p=0.0012) and (**C**) upon the expression in macrophages under *srpHemo-GAL4* control of an RNAi line (*v108288*) against Qsox1 (n = 24, 23 embryos, p=0.001). (**D**) Images from two-photon movies from control and *qsox1^KG04615^.* Macrophage nuclei (red) are labeled with *srpHemo-H2A::3xmCherry.* Stills at 0, 60, 90, 120, 150 and 180 min. (**E**) Quantification of macrophage speed reveals 18% slower macrophage migration in the head towards the yolk neighboring the germband in the *qsox1^KG04615^* mutant compared to the control (n = 3 movies for each, \#tracks: control = 329, mutant = 396, p=0.0056). (**F**) Quantification of the time required for macrophage entry into the germband in *qsox1^KG04615^* compared to the control. n = 3 movies for each, p=0.043. (**G**) Quantification of macrophage speed in the germband in the *qsox1^KG04615^* mutant compared to the control (n = 3 movies for each, \#tracks: control = 21, mutant = 19, p=0.300). (**H**) Pearson's Coefficient analysis indicating the level of colocalisation of a *MT-Qsox1::FLAG::HA* construct transfected into S2R+ cells visualized with an HA antibody and antibodies against markers for the ER (Cnx99a), the Golgi (Golgin 84, Golgin 245, and GMAP), the early endosome (Hrs), the late endosome (Rab7) and the nucleus (DAPI) (n = 11--15) as well as with a *srpHemo-mrva::3xmCherry* construct (n = 18). (**I**) Western blot of concentrated supernatant collected from S2R+ cells transfected with *srpGal4 UAS-qsox1::FLAG::HA* (first three lines) and S2R+ cells that are untransfected. (**J**) Quantification of intracellular LanA intensity along a 4 μm line in macrophages (as indicated in schematic) from the control (black), *minerva^3102^* (blue) and the *qsox1^KG04615^* mutants (orange) (n = 4--5 embryos, 80--100 cells, 240--300 lines). For the whole graph see [Figure 5---figure supplement 1G--J](#fig5s1){ref-type="fig"}. Scale bars 50 μm for A, 30 μm in D. B-C, E-G and J were analyzed with Student's test. ns = p \> 0.05, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001. See also [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.\
10.7554/eLife.41801.020Figure 5---source data 1.Source data on the quantification of macrophages in the germband shown in [Figure 5B-C](#fig5){ref-type="fig"}, on the yolk shown in [Figure 5---figure supplement 1A,1D](#fig5s1){ref-type="fig"}, on the vnc shown in [Figure 5---figure supplement 1B,1E](#fig5s1){ref-type="fig"}, and in the whole embryo shown in [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}.Source data on the xyz position of macrophages from the tracks that form the basis of the analysis shown in [Figure 5E-G](#fig5){ref-type="fig"}. Source data on the quantification of the Pearson\'s coefficient for Qsox1 colocalization with different markers shown in [Figure 5H](#fig5){ref-type="fig"} and the quantification of LanA intensity shown in [Figure 5J](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1L-N](#fig5s1){ref-type="fig"}. Source data on the xyz position of macrophages in the movies of the qsox1^KG04615^ mutant underlying the analysis shown in [Figure 5E-G](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1F](#fig5s1){ref-type="fig"}.](elife-41801-fig5){#fig5}

We wished to examine how Qsox1 could be exerting this effect on macrophage tissue entry. Vertebrate QSOX1 has been shown to localize to the Golgi and act as a sulfhydryl oxidase, catalyzing disulfide bond formation and protein folding ([@bib3]; [@bib26]; [@bib51]; [@bib56]). The *Drosophila* protein has been shown to be required for the secretion of multimerized EGF domains and was hypothesized to act redundantly with ER oxidoreductin-like-1 to form disulfide bonds ([@bib138]). We found that an HA-tagged form of Qsox1 transfected into the *Drosophila* macrophage like cell line, S2R+, colocalizes little with markers for the ER, and considerably with those for Golgi and endosomes ([Figure 5H](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1G--I](#fig5s1){ref-type="fig"}). We also observed significant colocalization with 3xmCherry-tagged Mrva ([Figure 5H](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1J](#fig5s1){ref-type="fig"}). Vertebrate QSOX1 can be cleaved from its transmembrane domain to allow secretion ([@bib109]), and has been shown *in vitro* to be required extracellularly for the incorporation of laminin produced by fibroblasts into the extracellular matrix (ECM), thereby supporting efficient cancer cell migration ([@bib61]). *Drosophila* Qsox1 also has a transmembrane domain, yet we detected an HA-tagged form in the media after transfection into S2R+ cells ([Figure 5I](#fig5){ref-type="fig"}), indicating that it can be secreted. To examine if *Drosophila* Qsox1 might also affect Laminin, we stained *mrva^3102^* and *qsox1^KG046152^* mutant embryos with an antibody against Laminin A (LanA) ([Figure 5---figure supplement 1K](#fig5s1){ref-type="fig"}). In both mutants we observed increased amounts of LanA inside and somewhat higher levels adjacent to the macrophages, but no significant alteration at the cell edges compared to the control ([Figure 5J](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1L--N](#fig5s1){ref-type="fig"}). We conclude that *Drosophila* Qsox1 can be secreted but is also found in the Golgi and endosomes like Mrva, and that both proteins affect LanA, a component of the ECM.

Conservation of Minerva's function in macrophage invasion and T antigen modification by its mammalian ortholog MFSD1 {#s2-7}
--------------------------------------------------------------------------------------------------------------------

To determine if our studies could ultimately be relevant for mammalian biology and therefore also cancer research, we searched for a mammalian ortholog. MFSD1 from *mus musculus* shows strong sequence similarity with Mrva, with 50% of amino acids displaying identity and 68% conservation ([Figure 6A](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). A transfected C-terminally GFP-tagged form ([Figure 6---figure supplement 1B](#fig6s1){ref-type="fig"}) showed localization to the secretory pathway, colocalizing with the Golgi marker GRASP65 in murine MC-38 colon carcinoma, 4T1 breast cancer cells and LLC1.1 lung cancer ([Figure 6B--C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1C--E](#fig6s1){ref-type="fig"}) and with Golgi and endosomal markers in B16-BL6 melanoma cells ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1F](#fig6s1){ref-type="fig"}). mmMFSD1 expression in macrophages in *mrva^3102^* mutant embryos can completely rescue the germband invasion defect ([Figure 6D--E](#fig6){ref-type="fig"}). This macrophage-specific expression of MFSD1 also resulted in higher levels of T antigen on macrophages when compared to those in *mrva^3102^* mutants ([Figure 6F--G](#fig6){ref-type="fig"}). Thus MFSD1 not only displays localization in the Golgi apparatus in multiple types of mammalian cancer but can also rescue O-glycosylation and migration defects when expressed in *Drosophila*, arguing that the functions Mrva carries out to promote invasion into the germband are conserved up to mammals.

![Minerva's murine ortholog, MFSD1, can substitute for Minerva's functions in migration and T-antigen glycosylation.\
(**A**) Topology prediction of mouse MFSD1 (NP_080089.1) using the online tools TMPred ([@bib55]) and Protter ([@bib95]). 50% of amino acids are identical between the *M. musculus* MFSD1 and *D. melanogaster* sequence of *mrva (CG8602)* (NP_648103.1) and are highlighted in dark blue, similar amino acids are in light blue. (**B**) Confocal images of MC-38 colon carcinoma cells showing colocalization of MFSD1-eGFP (green) with the Golgi marker GRASP65 (red). DAPI labels the nucleus (blue). (**C**) Quantitation using Fiji of the colocalization of MFSD1-eGFP with the Golgi marker (GRASP65), early endosome marker (Rab5), late endosome marker (Rab7), and lysosome marker (LAMP1) in MC-38 colon carcinoma, B16-BL6 melanoma, LLC1 Lewis lung carcinoma, and 4T1 breast carcinoma cells. Representative images are shown in [Figure 6---figure supplement 1C--F](#fig6s1){ref-type="fig"} (n = 8--15, 5--9, 4--9, 5--10 cells per condition within the respective cancer types). (**D**) Confocal image of a Stage 12 fixed embryo showing that expression of *mmMFSD1* in macrophages under the direct control of the *srpHemo(macro)* promoter in the *mrva^3102^* mutant can rescue the defect in macrophage migration into the germband. Compare to [Figure 3A,B](#fig3){ref-type="fig"}. Macrophages visualized with *srpHemo-H2A::3xmCherry* for D-E. (**E**) Quantitation of the number of macrophages in the germband of early Stage 12 embryos from the control (n = 25), *mrva^3102^* mutants (n = 29), and *mrva^3102^ srpHemo(macro)-mmMFSD1* (n = 13, p=0.0005 for mutant vs control, p\<0.0001 for mutant vs rescue). (**F**) Quantification of T antigen levels on macrophages in late Stage 11 embryos from control, *mrva^3102^*mutant and *mrva^3102^ srpHemo(macro)-mmMFSD1* embryos. T antigen levels normalized to those observed in the control (n = 8--9 embryos, 280, 333, and 289 cells quantified respectively, p\<0.0001 for both). (**G**) Confocal images of macrophages (red) on the germband border stained with T antigen antibody (green) in the control, the *mrva^3102^* mutant, and *mrva^3102^ srpHemo(macro)-mmMFSD1* shows that mmMFSD1 expression in macrophages can rescue the decrease of macrophage T antigen observed in the *mrva^3102^* mutant. Macrophages visualized with *srpHemo-3xmCherry* for F-G. (**H**) Model for Minerva's function during macrophage invasion based on our findings and the literature: Minerva in the Golgi (grey) leads to increases in T antigen levels on a subset of proteins that aid invasion, including Qsox1 which regulates protein folding through disulfide bond formation and isomerization. We propose that increased T antigen on Qsox1 facilitates its sulfhydryl oxidase activity that aids the formation of a robust crosslinked ECM which macrophages utilize during tissue entry. Significance was assessed by Kruskal-Wallis test with Conover post test analysis in **E,F**). \*\*\*p\<0.001, \*\*\*\*p\<0.0001. Scale bars are 10 μm in B, 50 μm in D, and 3 μm in G. See also [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.\
10.7554/eLife.41801.024Figure 6---source data 1.Source data on the quantification of Pearson's coefficient for MFSD1 colocalization with different markers ([Figure 6C](#fig6){ref-type="fig"}), the number of macrophages in the germband ([Figure 6E](#fig6){ref-type="fig"}) and the level of T antigen in macrophages ([Figure 6F](#fig6){ref-type="fig"}).](elife-41801-fig6){#fig6}

Discussion {#s2-8}
----------

O-glycosylation is one of the most common posttranslational modifications, yet the intrinsic technical challenges involved in identifying O-glycosites and altered O-glycosylation on a proteome-wide level has hampered the discovery of biological functions ([@bib75]). Here we provide two important new advances for the field. First, we identify a key regulator of this O-glycosylation, Minerva, with an unexpected role for a member of the major facilitator superfamily. Our demonstration that this conserved protein affects invasion and the appearance of the cancer-associated core1 T glycoform on a set of proteins connected to invasion provides a new perspective on T glycoform regulation and may have implications for cancer. Second, we define the GalNAc-type O-glycoproteome of *Drosophila* embryos. As O-glycosites cannot as yet be reliably predicted, our proteomic characterization in a highly genetically accessible organism will permit future studies on how glycosylation affects cell behavior; we highlight T and Tn O-glycosylated receptors in [Supplementary file 3](#supp3){ref-type="supplementary-material"} to further this goal.

Modifications of the O-glycoproteome by an MFS family member {#s2-9}
------------------------------------------------------------

Our identification of a MFS family member as a regulator of O-glycosylation is surprising. MFS family members can serve as transporters and shuttle a wide variety of substrates ([@bib104]; [@bib106]). Minerva displays homology to sugar transporters and is localized to the Golgi and endosomes. Minerva could thus affect O-glycosylation in the Golgi through substrate availability. However, the lower and higher levels of glycosylation in the *mrva^3102^* mutant we observe are hard to reconcile with this hypothesis. Given that the changes in T antigen on individual glycosites in the *mrva* mutant are found either with no significant change in Tn or with a change in the same direction ([Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}), regulation appears to occur at the initial GalNAc addition on the protein subset as well as on further T antigen elaboration. 95% of the proteins with 10-fold altered glycosylation in the *mrva* mutant had multiple O-glycosylation sugar modifications compared to 56% of the general O-glycoproteome. Greatly enhanced glycosylation of protein sequences containing an existing glycan modification is observed for some GalNAc-Ts due to a lectin domain ([@bib49]; [@bib70]; [@bib107]) and Minerva could theoretically affect such a GalNAc-T in *Drosophila*. Alternatively, Minerva, while in the 'outward open' conformation identified for MFS structures ([@bib104]), may itself have a lectin-like interaction with Tn and T glycoforms that have already been added on a loop of particular proteins. Minerva's binding could open up the target protein's conformation to increase or block access to other potential glycosites and thus affect the final glycosylation state on select glycoproteins.

The changes we see in O-glycosylation are also likely due to a combination of Minerva's direct and indirect effects. O-GalNAc modification of vertebrate Notch can affect Notch signaling during development ([@bib17]); the *Drosophila* ortholog of the responsible GalNAc transferase is also essential for embryogenesis ([@bib12]; [@bib115]). A GalNAcT in *Xenopus* can glycosylate a peptide corresponding to the ActR IIB receptor and inhibit Activin and BMP type signaling ([@bib53]; [@bib145]). Thus the changed glycosylation we observe on components of the Notch and Dpp pathways could alter transcription ([@bib47]; [@bib93]), shifting protein levels and thereby changing the ratio of some glycopeptides in the *mrva* mutant relative to the wild type. Proteins in which glycosylation at other sites is unchanged or changed in the opposite direction are those most likely to be directly affected by Minerva. Such proteins include ones involved in protein folding and O-glycan addition and removal ([Figure 4H](#fig4){ref-type="fig"}) ([@bib138]). If changes in the glycosylation of these proteins alters their specificity or activity, some of the shifts we observe in our glycoproteomic analysis could be indirect in a different way; an initial effect of Minerva on the glycosylation of regulators of protein folding and glycosylation could change how these primary Minerva targets affect the glycosylation of a second wave of proteins.

An invasion program regulated by Minerva {#s2-10}
----------------------------------------

The truncated immature core1 T and Tn O-glycans are not usually present in normal human tissues but exposure of these uncapped glycans has been found on the majority of cancers and serves as a negative indicator of patient outcome ([@bib38]; [@bib124]). Increases in Tn antigen due to a shift in GalNAcT localization to the ER promote invasion and metastasis ([@bib41]). An antibody against T antigen has decreased the metastatic spread of cancer cells in mice ([@bib52]). Here we further strengthen the case for a causative relationship between T antigen modification and the invasive migration that underlies metastasis. The transient appearance of T antigen in human fetuses ([@bib11]) and the conserved function of Minerva lead us to propose that the change in O-glycosylation in cancer represents the reactivation of an ancient developmental program for invasion. Our embryonic glycoproteome analysis identifies 106 T antigen modified proteins, a very large set to investigate. However, the absence of Mrva causes invasion defects and deficits in T antigen modification on only 10--20 proteins; these include components involved in protein folding, glycosylation modification, and the signaling pathways triggered by Notch and the BMP family member, Dpp.

Our working model is that the defect in germband tissue invasion seen in the *mrva* mutant is caused by the absence of T antigen on this group of proteins that act coordinately ([Figure 6H](#fig6){ref-type="fig"}). 56% of these have vertebrate orthologs, and 55% of those have already been linked to cancer and metastasis. The vertebrate ortholog of Qsox1, the protein with the largest changes in T antigen in the *mrva* mutant, can enhance cancer cell invasion in *in vitro* assays and higher levels of the protein have been associated with poor patient outcomes ([@bib66]; [@bib65]). We find that the strongest effect of *Drosophila* Qsox1 on macrophage migration is to reduce the time by two fold that macrophages take sitting at the germband edge before they successfully begin to invade into the germband tissues. We also observe in *qsox1* and *mrva* mutants that LanA levels are higher within the macrophages and somewhat elevated near but not at the macrophage cell edges. This could be due to some combination of the following shifts in cellular processes: an increase in LanA production, a decrease in its degradation, a slowing of its secretion or a speeding of its diffusion. We base our model on the functions that have been previously defined for the Qsox1 sulfhydryl oxidase family, in integrating laminin into the ECM ([@bib61]) and aiding secretion of EGF domains ([@bib138]) which are found in *Drosophila* Laminins. If Qsox1 is needed for the efficient secretion and integration of LanA into the ECM, its absence could result in a less robustly cross-linked matrix. ECM crosslinking has been shown to enhance Integrin signaling, focal adhesion formation, and invasion of mammalian tumor cells ([@bib74]). In its absence *Drosophila* macrophages which utilize Integrin during invasion ([@bib121]) and whose invasive migration is accompanied by deformation of the flanking tissue ([@bib105]), could be unable to generate sufficient traction forces to enter. Indeed, mutating another subunit of the *Drosophila* Laminin trimer, LanB1, reduces both normal LanA deposition and germband invasion by macrophages ([@bib85]; [@bib111]). A determination of the effect of Minerva's regulation awaits a characterization of Qsox1 mutated such that it is incapable of being modified by T antigen on the Mrva-dependent sites. Nonetheless, the similarity of the changes in LanA we observe in the *mrva^3102^* and *qsox1^KG046152^* mutant supports the conclusion that Mrva dependent T-antigen modification of Qsox1 is necessary for its activity on some substrates. Given that *mrva^3102^* mutants take even longer than *qsox1^KG04615^* to enter germband tissue and display much stronger defects thereafter, we propose that T antigen modifications on other proteins are also crucial for tissue entry, and underlie the defect in invasive migration within the germband.

Minerva's vertebrate ortholog, MFSD1, can rescue macrophage migration defects and restores higher T antigen levels. Tagged versions of Minerva's vertebrate ortholog, MFSD1, detected the protein in lysosomes in HeLa and rat liver cells ([@bib27]; [@bib99]). In four metastasizing mouse tumor cell lines we find MFSD1 mainly in the Golgi, where O-glycosylation is known to occur ([@bib13]). We do not yet know if invasion and metastasis is altered by the absence of MFSD1 but will be testing this in future work. Akin to how kinases add phospho-groups to affect a set of proteins and orchestrate a particular cellular response, we propose that Minerva in *Drosophila* macrophages and its vertebrate ortholog MFSD1 in cancer trigger changes in O-glycosylation that coordinately modulate, activate and inhibit a protein group to affect cellular dissemination and tissue invasion.

Materials and methods {#s3}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Designation                              Source or reference                                                                                                                                                Identifiers                                                                                 Additional\
                                                                                                                                                                                                                                                                                                          information
  ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  *mrva*                                   NA                                                                                                                                                                 FlyBase:FBgn0035763                                                                         

  *qsox1*                                  NA                                                                                                                                                                 FlyBase: FBgn0033814                                                                        

  *C1GalTA*                                NA                                                                                                                                                                 FlyBase: FBgn0032078                                                                        

  *srp-Gal4*                               PMID: 15239955                                                                                                                                                                                                                                                 

  *srp-3xmCherry*                          PMID: 29321168                                                                                                                                                     RRID:[BDSC_78358](https://scicrunch.org/resolver/BDSC_78358) and 78359                      

  *srp-H2A::3xmCherry*                     PMID: 29321168                                                                                                                                                     RRID:[BDSC_78360](https://scicrunch.org/resolver/BDSC_78360) and 78361                      

  *UAS-CG8602::FLAG::HA*                   PMID: 22036573                                                                                                                                                                                                                                                 

  *mrva^3102^*                             Bloomington Drosophila Stock Center (BDSC), RRID:[SCR_006457](https://scicrunch.org/resolver/SCR_006457)                                                           RRID:[BDSC_17262](https://scicrunch.org/resolver/BDSC_17262)                                

  *Df(3L)BSC117*                           BDSC, RRID:[SCR_006457](https://scicrunch.org/resolver/SCR_006457)                                                                                                 RRID:[BDSC_8976](https://scicrunch.org/resolver/BDSC_8976)                                  

  *UAS-mCherry.NLS*                        BDSC, RRID:[SCR_006457](https://scicrunch.org/resolver/SCR_006457)                                                                                                 RRID:[BDSC_38425](https://scicrunch.org/resolver/BDSC_38425)                                

  *C1GalTA2.1*                             BDSC, RRID:[SCR_006457](https://scicrunch.org/resolver/SCR_006457)                                                                                                 RRID:[BDSC_28834](https://scicrunch.org/resolver/BDSC_28834)                                

  *C1GalTA RNAi 1*                         Vienna Drosophila Resource Centre (VDRC), RRID:[SCR_013805](https://scicrunch.org/resolver/SCR_013805)                                                             VDRC: 2826                                                                                  

  *C1GalTA RNAi 2*                         VDRC, RRID:[SCR_013805](https://scicrunch.org/resolver/SCR_013805)                                                                                                 VDRC: 110406                                                                                

  *CG8602 RNAi*                            VDRC, RRID:[SCR_013805](https://scicrunch.org/resolver/SCR_013805)                                                                                                 VDRC: 101575                                                                                

  *qsox1RNAi*                              VDRC, RRID:[SCR_013805](https://scicrunch.org/resolver/SCR_013805)                                                                                                 VDRC: 108288                                                                                

  *qsox1 KG04615*                          BDSC, RRID:[SCR_006457](https://scicrunch.org/resolver/SCR_006457)                                                                                                 RRID:[BDSC_13824](https://scicrunch.org/resolver/BDSC_13824)                                

  MC-38                                    Other                                                                                                                                                                                                                                                          Gift from Borsig lab, Univ of Zurich (UZH)

  4T1                                      Other                                                                                                                                                              ATCC Cat\# CRL-2539, RRID:[CVCL_0125](https://scicrunch.org/resolver/CVCL_0125)             Gift from Borsig lab, UZH

  LLC1                                     Other                                                                                                                                                              ATCC Cat\# CRL-1642, RRID:[CVCL_4358](https://scicrunch.org/resolver/CVCL_4358)             Gift from Borsig lab, UZH

  B16-BL6                                  Other                                                                                                                                                              NCI-DTP Cat\# B16BL-6, RRID:[CVCL_0157](https://scicrunch.org/resolver/CVCL_0157)           Gift from Borsig lab, UZH

  S2R+                                     Other                                                                                                                                                                                                                                                          Gift from Frederico Mauri of the Knoblich lab at IMBA, Vienna

  *srpHemo-CG8602::3xmCherry*              this paper                                                                                                                                                                                                                                                     CG8602 amplified from genome cloned into DSPL172 (PMID: 29321168)

  *MT-CG8602::FLAG::HA*                    Drosophila Genomic Resource Center (DGRC), RRID:[SCR_002845](https://scicrunch.org/resolver/SCR_002845)                                                            DGRC: FMO06045                                                                              

  *MT-Qsox1::FLAG::HA*                     DGRC, RRID:[SCR_002845](https://scicrunch.org/resolver/SCR_002845)                                                                                                 DGRC: FMO06379                                                                              

  *PTS1-GFP*                               Other                                                                                                                                                                                                                                                          Gift from Dr. McNew

  *MFSD1-eGFP*                             this paper                                                                                                                                                                                                                                                     MFSD1 amplified from dendritic cell cDNA library, inserted into Doxycycline inducible\
                                                                                                                                                                                                                                                                                                          expression vector pInducer20

  Anti-GFP clone 2B6                       Other                                                                                                                                                                                                                                                          Gift from Ogris lab, MFPL Vienna; (1:100) for WB

  Anti-GFP clone 5G4                       Other                                                                                                                                                                                                                                                          Gift from Ogris lab, MFPL Vienna; (1:50) for immunochemistry

  Anti-T-antigen (mouse monoclonal)        PMID: 23584533                                                                                                                                                                                                                                                 (1:5 for\
                                                                                                                                                                                                                                                                                                          immunochemistry; 1:10 for WB)

  Anti-profilin (mouse monoclonal)         Developmental Studies\                                                                                                                                             DSHB Cat\# chi 1J, RRID:[AB_528439](https://scicrunch.org/resolver/AB_528439)               (1:50)
                                           Hybridoma Bank (DSHB), RRID:[SCR_013527](https://scicrunch.org/resolver/SCR_013527)                                                                                                                                                                            

  Anti-GAPDH (rabbit monoclonal)           Abcam, RRID:[SCR_012931](https://scicrunch.org/resolver/SCR_012931)                                                                                                Abcam Cat\# ab181603, RRID:[AB_2687666](https://scicrunch.org/resolver/AB_2687666)          (1:10000) for WB

  Anti-GRASP65 (rabbit polyclonal)         Thermo Fisher Scientific, RRID:[SCR_008452](https://scicrunch.org/resolver/SCR_008452)                                                                             ThermoFischer Cat\# PA3-910, RRID:[AB_2113207](https://scicrunch.org/resolver/AB_2113207)   (1:200) for immunochemistry

  Anti-Rab5 (rabbit monoclonal)            Cell Signaling Technology (CST), RRID:[SCR_004431](https://scicrunch.org/resolver/SCR_004431), Clone C8B1                                                          CST Cat\# 3547, RRID:[AB_2300649](https://scicrunch.org/resolver/AB_2300649)                (1:200) for immunochemistry

  Anti-Rab7 (rabbit monoclonal)            CST, RRID:[SCR_004431](https://scicrunch.org/resolver/SCR_004431), Clone D95F2                                                                                     CST Cat\# 9367, RRID:[AB_1904103](https://scicrunch.org/resolver/AB_1904103)                (1:200) for immunochemistry

  Anti-LAMP1 (rabbit polyclonal)           Abcam, RRID:[SCR_012931](https://scicrunch.org/resolver/SCR_012931)                                                                                                Abcam Cat\# ab24170, RRID:[AB_775978](https://scicrunch.org/resolver/AB_775978)             (1:200) for immunochemistry

  Anti- Cnx99a (mouse monoclonal)          DSHB, RRID:[SCR_013527](https://scicrunch.org/resolver/SCR_013527)                                                                                                 DSHB Cat\# Cnx99A 6-2-1, RRID:[AB_2722011](https://scicrunch.org/resolver/AB_2722011)       (1:5)

  Anti- Hrs 27.4 (mouse monoclonal)        DSHB, RRID:[SCR_013527](https://scicrunch.org/resolver/SCR_013527)                                                                                                 DSHB Cat\# Hrs 27--4, RRID:[AB_2618261](https://scicrunch.org/resolver/AB_2618261)          (1:5)

  Anti- Golgin 84\                         DSHB, RRID:[SCR_013527](https://scicrunch.org/resolver/SCR_013527)                                                                                                 DSHB Cat\# Golgin8412--1, RRID:[AB_2722113](https://scicrunch.org/resolver/AB_2722113)      (1:5)
  (mouse monoclonal)                                                                                                                                                                                                                                                                                      

  Anti Rab7 (mouse monoclonal)             DSHB, RRID:[SCR_013527](https://scicrunch.org/resolver/SCR_013527)                                                                                                 DSHB Cat\# Rab7, RRID:[AB_2722471](https://scicrunch.org/resolver/AB_2722471)               (1:5)

  Anti-GMAP (goat polyclonal)              DSHB, RRID:[SCR_013527](https://scicrunch.org/resolver/SCR_013527)                                                                                                 DSHB Cat\# GMAP, RRID:[AB_2618259](https://scicrunch.org/resolver/AB_2618259)               (1:50)

  Anti- Golgin 245 (goat polyclonal)       DSHB, RRID:[SCR_013527](https://scicrunch.org/resolver/SCR_013527)                                                                                                 DSHB Cat\# Golgin245, RRID:[AB_2618260](https://scicrunch.org/resolver/AB_2618260)          (1:50)

  Anti- HA (rat monoclonal)                Roche, RRID:[SCR_001326](https://scicrunch.org/resolver/SCR_001326)                                                                                                Roche Cat\# 3F10, RRID:[AB_2314622](https://scicrunch.org/resolver/AB_2314622)              (1:50)

  Anti-LanA (rabbit polyclonal)            PMID:9257722                                                                                                                                                                                                                                                   gift from Stefan Baumgartner\
                                                                                                                                                                                                                                                                                                          (1:500)

  Anti-Vasa (rat monoclonal)               DSHB, RRID:[SCR_013527](https://scicrunch.org/resolver/SCR_013527)                                                                                                 DSHB Cat\# anti-vasa, RRID:[AB_760351](https://scicrunch.org/resolver/AB_760351)            (1:25)

  Alexa 488- or 557- or 633- secondaries   Thermo Fisher Scientific, RRID:[SCR_008452](https://scicrunch.org/resolver/SCR_008452)                                                                                                                                                                         (1:500 for 488 and 557; 1:100 for 633)

  Goat-anti-rabbit IgG (H + L)-HRP         BioRad                                                                                                                                                             Bio-Rad Cat\# 170--6515, RRID:[AB_2617112](https://scicrunch.org/resolver/AB_2617112)       (1:10000)

  Goat-anti-mouse IgG (H/L):HRP            BioRad                                                                                                                                                             Bio-Rad Cat\# 170--6516, RRID:[AB_11125547](https://scicrunch.org/resolver/AB_11125547)     (1:10000)

  LysoTracker Green DND-26                 Invitrogen, RRID:[SCR_008410](https://scicrunch.org/resolver/SCR_008410)                                                                                           L7526                                                                                       75 nM

  Alexa Fluor 488 Phalloidin               Invitrogen, RRID:[SCR_008410](https://scicrunch.org/resolver/SCR_008410)                                                                                           A12379                                                                                      (1:500)

  Vectashield mounting medium              Vector Laboratories, RRID:[SCR_000821](https://scicrunch.org/resolver/SCR_000821)                                                                                  VectorLabs: H-1000                                                                          

  Vectashield mounting medium with DAPI    Vector Laboratories, RRID:[SCR_000821](https://scicrunch.org/resolver/SCR_000821)                                                                                  VectorLabs: H-1200                                                                          

  Halocarbon Oil 27                        Sigma-Aldrich, RRID:[SCR_008988](https://scicrunch.org/resolver/SCR_008988)                                                                                        Sigma Aldrich: Cat\# H8773                                                                  

  *srpHemo-mrva*                           this paper                                                                                                                                                                                                                                                     CG8602 amplified from genome cloned into srpHemo plasmid

  *srpHemo-MFSD1*                          this paper                                                                                                                                                                                                                                                     mmMFSD1 amplified from dendritic cell cDNA library cloned into srpHemo plasmid

  Mrva fw                                  Fly Primer Bank                                                                                                                                                                                                                                                qPCR; 5\'TGTGCTTCGTGGGAGGTTTC

  Mrva rv                                  Fly Primer Bank                                                                                                                                                                                                                                                qPCR; 5\'GCAGGCAAAGATCAACTGACC

  C1GalTA fw                               Fly Primer Bank                                                                                                                                                                                                                                                qPCR; 5\'TGCCAACAGTCTGCTAGGAAG

  C1GalTA rv                               Fly Primer Bank                                                                                                                                                                                                                                                qPCR: 5\'CTGTGATGTGCATCGTTCACG

  Ugalt fw                                 Fly Primer Bank                                                                                                                                                                                                                                                qPCR; 5\'GCAAGGATGCCCAGAAGTTTG

  Ugalt rv                                 Fly Primer Bank                                                                                                                                                                                                                                                qPCR; 5\'GATATAGACCAGCGAGGGGAC

  RpL32 fw                                 Fly Primer Bank                                                                                                                                                                                                                                                qPCR; 5\'AGCATACAGGCCCAAGATCG

  RpL32 rv                                 Fly Primer Bank                                                                                                                                                                                                                                                qPCR; 5\'TGTTGTCGATACCCTTGGGC

  Lectin staining kit \#2                  EY Laboratories                                                                                                                                                    EYLabs:FLK-002                                                                              

  FIJI                                     <http://fiji.sc/>\                                                                                                                                                                                                                                             
                                           RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285))                                                                                                                                                                                                  

  Imaris                                   <http://www.bitplane.com/imaris/imaris>, RRID:[SCR_007370](https://scicrunch.org/resolver/SCR_007370)                                                                                                                                                          

  Matlab                                   <https://www.mathworks.com/products/matlab.html>,\                                                                                                                                                                                                             
                                           RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)                                                                                                                                                                                                   

  FlowJo                                   <https://www.flowjo.com/RRID>:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)                                                                                                                                                                          

  LaVision ImSpector                       <http://www.lavisionbiotec.com/>,\                                                                                                                                                                                                                             
                                           RRID:[SCR_015249](https://scicrunch.org/resolver/SCR_015249)                                                                                                                                                                                                   

  Proteome Discoverer 1.4                  [https://www.thermofisher.com/order/](https://www.thermofisher.com/order/catalog/product/OPTON-30795)\                                                                                                                                                         
                                           [catalog/product/OPTON-30795](https://www.thermofisher.com/order/catalog/product/OPTON-30795), RRID:[SCR_014477](https://scicrunch.org/resolver/SCR_014477)                                                                                                    

  LightCycler 480 software                 [https://lifescience.roche.com/en_at/products/lightcycler14301-480](https://lifescience.roche.com/en_at/products/lightcycler14301-480-software-version-15.html)\                                                                                               
                                           [-software-version-15.html](https://lifescience.roche.com/en_at/products/lightcycler14301-480-software-version-15.html)                                                                                                                                        

  GraphPad Prism                           <https://www.graphpad.com/scientific-software/prism/>\                                                                                                                                                                                                         
                                           RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                                                                                                                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Fly work {#s3-1}
--------

Flies were raised on food bought from IMBA (Vienna, Austria) which contained the standard recipe of agar, cornmeal, and molasses with the addition of 1.5% Nipagin. Adults were placed in cages in a Percival DR36VL incubator maintained at 29°C and 65% humidity; embryos were collected on standard plates prepared in house from apple juice, sugar, agar and Nipagin supplemented with yeast from Lesaffre (Marcq, France) on the plate surface. Embryo collections for fixation (7 hr collection) as well as live imaging (4.5 hr collection) were conducted at 29°C.

### Fly Lines utilized {#s3-1-1}

*srpHemo-GAL4* was provided by K. Brückner (UCSF, USA) ([@bib19]), *UAS-CG8602::FLAG::HA* (from K. VijayRaghavan National Centre for Biological Sciences, Tata Institute of Fundamental Research) ([@bib45]). The stocks *w^1118^; minerva^3102^* (BDSC-17262), (*pn^1^;; ry^503^Dr^1^*P\[Δ 2--3\] (BDSC-1429), *Df(3L)BSC117* (BDSC-8976), *Oregon R* (BDSC-2375), *w^-^; P{w\[+mC\]=UAS mCherry.NLS}2;MKRS/Tm6b, Tb(1)* (BDSC-38425), *w^-^,P{UAS-Rab11-GFP}2* (BDSC-8506), *y(1) sc\[\*\] v(1); P{y\[+t7.7\] v\[+t1.8\]=TRiP .GL00069}attP2* (BDSC-35195), *y(1) w\[\*\]; Mi{y\[+mDint2\]=MIC}GlcAT-P\[MI05251\]/TM3, Sb(1)* (BDSC-40779) were obtained from the Bloomington *Drosophila* Stock Centre, Bloomington, USA. The RNAi lines v60100, v110406, v2826, v101575 were obtained from the Vienna Drosophila Resource Center (VDRC), Vienna, Austria. Lines *w^-^; P{w\[+mC; srpHemo-3xmCherry}*, *w^-^; P{w\[+mC; srpHemo-H2A::3xmCherry}* were published previously ([@bib46]).

Exact genotype of *Drosophila* lines used in figures {#s3-2}
----------------------------------------------------

[Figure 1D-H:](#fig1){ref-type="fig"} *w-; +; srpHemo-3xmCherry. *[Figure 1I-K](#fig1){ref-type="fig"}: Control: *w- P(w+)UAS-dicer**/**w-; P{attP,y\[+\],w\[3\`\]/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+.* C1GalTA RNAi: *w^-^ P(w+)UAS-dicer2/w-; RNAi C1GalTA (v110406)/+; srpHemo-Gal4 UAS-GFP UAS-H2A:RFP/+.* [Figure 1L](#fig1){ref-type="fig"}: Control: *w-; +; srpHemo-H2A::3xmCherry.* C1GalLTA mutant: *w-; C1GalTA^2.1^; srpHemo-H2A::3xmCherry.* [Figure 1M](#fig1){ref-type="fig"}: Control: *w-; srpHemo-H2A::3xmCherry.* GlcAT-P mutant: *w-; srpHemo-H2A::3xmCherry, Mi{MIC}GlcAT-PMI05251.*

[Figure 1---figure supplement 1A--L](#fig1s1){ref-type="fig"}*: w-; +; srpHemo-3xmCherry.* [Figure 1---figure supplement 1M, N, P](#fig1s1){ref-type="fig"}: Control: *w- UAS-Dicer2/w-; P{attP,y\[+\]w\[3\`\]/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+.* C1GalTA RNAi: *w-UAS-Dicer2/w-; RNAi C1GalTA (v110406)/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+*. [Figure 1---figure supplement 1O](#fig1s1){ref-type="fig"}: Control: *w-; +; srpHemo-H2A::3xmCherry.* C1GalTA mutant: *w-; C1GalTA^2.1^; srpHemo-H2A::3xmCherry*. [Figure 1---figure supplement 1P](#fig1s1){ref-type="fig"}: Control: *w- UAS-Dicer2/w-; P{attP,y\[+\]w\[3\`\]/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+.* C1GalTA RNAi: *w-UAS-Dicer2/w-; RNAi C1GalTA (v2826)/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+*. [Figure 1---figure supplement 1Q](#fig1s1){ref-type="fig"}: Control: *w-; srpHemo-H2A::3xmCherry.* GlcAT-P mutant: *w-; srpHemo-H2A::3xmCherry; Mi{MIC}GlcAT-PMI05251.*

[Figure 2A, B, D:](#fig2){ref-type="fig"} *w-; +; srpHemo-3xmCherry.* [Figure 2E, F, G](#fig2){ref-type="fig"}: Control: *w-; +; srpHemo-3xmCherry.* CG8602 mutant: *w-; +; srpHemo-3xmCherry,P{EP}CG8602^3102^.* [Figure 2I](#fig2){ref-type="fig"}: *w-; srpHemo-Gal4; UAS-CG8602::FLAG::HA.*

[Figure 3A:](#fig3){ref-type="fig"} *w-; +; srpHemo-H2A::3xmCherry.* [Figure 3B](#fig3){ref-type="fig"}: *w-; +; srpHemo-H2A::3xmCherry, P{EP}CG8602^3102^.* [Figure 3C](#fig3){ref-type="fig"}: *w-; srpHemo-CG8602; srpHemo-H2A::3xmCherry P{EP}CG8602^3102^.* [Figure 3D](#fig3){ref-type="fig"}: Contro*l: w-; srpHemo-Gal4 UAS-mCherry::nls; +*. CG8602 (Mrva) mutant*: w-; srpHemo-Gal4 UAS-mCherry::nls; P{EP}CG8602^3102^,* Df cross: *w-; srpHemo-Gal4 UAS-mCherry:nls; P{EP}CG8602^3102^/Df(3L)BSC117.* Rescue*: w-; srpHemo-Gal4 UAS-mCherry:nls; UAS-CG8602::FLAG::HA P{EP}CG8602^3102^*. Precise excision: *srpHemo-Gal4 UAS-mCherry:nls; P{EP}CG8602^3102^Δ32.* [Figure 3E](#fig3){ref-type="fig"}: Control: *w^-^ P(w+)UAS-dicer**/**+; +; srpHemo-Gal4 UAS-GFP UAS-H2A:RFP/+*. Mrva RNAi: *w- UAS-dicer2/w-; RNAi CG8602 (v101575)/+; srpHemo-Gal4 UAS-GFP UAS-H2A:RFP/+.* [Figure 3F](#fig3){ref-type="fig"}: Control: *w-; srpHemo-Gal4 UAS-mCherry::nls; +*. Mrva mutant: *w-; srpHemo-Gal4 UAS-mCherry::nls; P{EP}CG8602^3102^*. [Figure 3G](#fig3){ref-type="fig"}: Control: *w-; +; srpHemo-3xmCherry.* Mrva mutant: *w-; +; srpHemo-3xmCherry P{EP}CG8602^3102^.* Cadherin Mrva double mutant: *w-; shg^P34^; srpHemo-3xmCherry P{EP}CG8602^3102^.* [Figure 3H](#fig3){ref-type="fig"}: Control: *w-; +; srpHemo-3xmCherry.* Mrva mutant: *w-; +; srpHemo-3xmCherry P{EP}CG8602^3102^*. [Figure 3I-M](#fig3){ref-type="fig"}: Control: *w-; +; srpHemo-H2A::3xmCherry.* Mrva mutant: *w-; +; srpHemo-H2A::3xmCherry P{EP}CG8602^3102^.*

[Figure 3-figure supplement 1A:](#fig3s1){ref-type="fig"} Control: *w-; +; srpHemo-H2A::3xmCherry.* Mrva mutant: *w-; +; srpHemo-H2A::3xmCherry P{EP}CG8602^3102^.* Rescue: *w-; srp-CG8602; srpHemo-H2A::3xmCherry P{EP}CG8602^3102^.* [Figure 3-figure supplement 1B, C, E](#fig3s1){ref-type="fig"}: Control: *w-; +; srpHemo-Gal4 UAS-GFP UAS-H2A:RFP/+.* Mrva RNAi: *w-; RNAi CG8602 (v101575)/+; srpHemo-Gal4 UAS-GFP UAS-H2A::RFP/+.* [Figure 3-figure supplement 1D, F-G](#fig3s1){ref-type="fig"}: Control: *w-; +; srpHemo-H2A::3xmCherry.* Mrva mutant: *w-; +; srpHemo-H2A::3xmCherry P{EP}CG8602^3102^.* [Figure 3-figure supplement 1H-L](#fig3s1){ref-type="fig"}: Control: *w-; +; srpHemo-3xmCherry.* Mrva mutant: *w-; +; srpHemo-3xmCherry P{EP}CG8602^3102^*

[Figure 4A-I:](#fig4){ref-type="fig"} Control: *w-; +, srpHemo-3xmCherry*. Mrva mutant: *w-; +, srpHemo-3xmCherry P{EP}CG8602^3102^.*

[Figure 5A-B:](#fig5){ref-type="fig"} Control: *w-; +; srpHemo-3xmCherry.* Qsox1 mutant: *w-;P{SUPor-P}Qsox1KG04615; srpHemo-3xmCherry.* [Figure 5C](#fig5){ref-type="fig"}: *w/y,w\[1118\]; P{attP,y\[+\],w\[3\`\]}/srpHemo-Gal4; srpHemo-H2A::3xmCherry/+.*Qsox1 RNAI: *w-/y,w\[1118\]; v108288/srpHemo-Gal4; srpHemo-H2A::3xmCherry/+.* [Figure 5D-G](#fig5){ref-type="fig"}: Control: *w-; +; srpHemo-H2A::3xmCherry.* Qsox1 mutant: *w-;P{SUPor-P}Qsox1KG04615; srpHemo-H2A::3xmCherry*. [Figure 5J](#fig5){ref-type="fig"}: Control: *w-; +; srpHemo-3xmCherry.* Mrva mutant: *w-; +; srpHemo-3xmCherry P{EP}CG8602^3102^.* Qsox1 mutant: *w-; P{SUPor-P}Qsox1KG04615;srpHemo-3xmCherry.*

[Figure 5-figure supplement 1A-B](#fig5s1){ref-type="fig"}: Control: *w-; +; srpHemo-3xmCherry.* Qsox1 mutant: *w-;P{SUPor-P}Qsox1KG04615; srpHemo-3xmCherry.* [Figure 5-figure supplement 1C, F](#fig5){ref-type="fig"}: *w-; +; srpHemo-H2A::3xmCherry, w-; P{SUPor-P}Qsox1KG04615; srpHemo-H2A::3xmCherry.* [Figure 5-figure supplement 1D-E](#fig5){ref-type="fig"}: Control: *w-/y,w\[1118\]; P{attP,y\[+\],w\[3\`\]}/srpHemo-Gal4; srpHemo-H2A::3xmCherry/+.* Qsox1 RNAi: *w-/y,w\[1118\]; v108288/srpHemo-Gal4; srpHemo-H2A::3xmCherry/+.* Figure 5-figure supplement 1K-N: Control: *w-; +; srpHemo-3xmCherry.* Mrva mutant: *w-; +; srpHemo-3xmCherry P{EP}CG8602^3102^,* Qsox1 mutant: *w-; P{SUPor-P}Qsox1KG04615; srpHemo-3xmCherry.*

[Figure 6D:](#fig6){ref-type="fig"} *w-; srpHemo-MFSD1; srpHemo-H2A::3xmCherry P{EP}CG8602^3102^.* [Figure 6E](#fig5){ref-type="fig"}: Control: *w-; +; srpHemo-H2A::3xmCherry.* Mrva mutant: *w-; +; srpHemo-H2A::3xmCherry P{EP}CG8602^3102^.* MFSD1 rescue*: w-; srpHemo-MFSD1; srpHemo-H2A::3xmCherry P{EP}CG8602^3102^.* [Figure 6F, G](#fig5){ref-type="fig"}: Control: *w-; +; srpHemo-3xmCherry.* Mrva mutant: *w-; +; srpHemo-3xmCherry P{EP}CG8602^3102^.* MFSD1 rescue*: w-; srpHemo-MFSD1; srpHemo-3xmCherry P{EP}CG8602^3102^*.

Embryo fixation and immunohistochemistry {#s3-3}
----------------------------------------

Embryos were collected on apple juice plates from between 6 and 8.5 hr at 29°C. Embryos were incubated in 50% Chlorox (DanClorix) for 5 min and washed. Embryos were fixed with 17% formaldehyde/heptane for 20 min followed by methanol or ethanol devitellinization except for T antigen analysis, when embryos were fixed in 4% paraformaldehyde/heptane. Fixed embryos were blocked in BBT (0.1M PBS + 0,1% TritonX-100 +0,1% BSA) for 2 hr at RT. Antibodies were used at the following dilutions: α-T antigen ([@bib128]) 1:5, α-GFP (Aves Labs Inc., Tigard, Oregon) 1:500; α-LanA ([@bib71]) (a gift from Stefan Baumgartner) 1:500; α-Vasa ([@bib6]) (DSHB, deposited by A. Sprading/D. Williams) 1:25; and incubated overnight at 4°C (GFP) or room temperature (T antigen, LanA). Afterwards, embryos were washed in BBT for 2 hr, incubated with secondary antibodies (Thermo Fisher Scientific, Waltham, Massachusetts, USA) at RT for 2 hr, and washed again for 2 hr. Vectashield (Vector Laboratories, Burlingame, USA) was then added. After overnight incubation in Vectashield at 4°C, embryos were mounted on a slide and imaged with a Zeiss Inverted LSM700 Confocal Microscope using a Plan-Apochromat 20X/0.8 Air Objective or a Plan-Apochromat 63X/1.4 Oil Objective.

Ovary dissection and immunostaining {#s3-4}
-----------------------------------

3--5 day old females were fed with yeast for 2 days at 25°C. For ovary dissection, females were anesthetized using the FlyNap anesthetic kit (Carolina, Burlington, NC, USA) and further transferred to ice cold PBS in which ovaries were extracted with pre-cleaned forceps. Individual ovaries were fixed in 4% Paraformaldehyde/PBS at room temperature (RT) for 20 min with agitation. Three wash steps with PBS at RT for 10 min were performed and individual ovaries were incubated in PBS supplemented with 0.1% of Triton X-100 (PBT) for 10 min at RT to allow permeabilization of the tissue. Ovaries were incubated in phalloidin-A488 (Thermo Fisher) diluted in PBT (1:300) overnight at 4°C. After being washed with PBT and PBS, ovaries were mounted in Vectashield + DAPI (LifeTechnologies, Carlsbad, USA).

Fixed ovary image analysis for border cell migration {#s3-5}
----------------------------------------------------

Ovaries were imaged as a Z-series (1 µm apart) with a Plan-Apochromat 20X/0.8 Air Objective on a Zeiss LSM700 inverted microscope. Images were acquired from stage 10 oocytes and maximum-intensity projections were created using ImageJ (NHI, USA). Border cells were identified by the clustered nuclei and their enriched actin staining. Border cell migration was quantified in the DAPI images as the percentage observed relative to the expected migration to the edge of the oocyte for these cells in stage 10 oocytes. Measurements were performed using ImageJ software (NIH, USA).

Lectin staining {#s3-6}
---------------

Embryos were fixed with 10% formaldehyde/heptane and devitellinized with Ethanol. Blocking was conducted in BBT for 2 hr at room temperature. A FITC-labeled lectin kit \#2 (EY laboratories, San Mateo, CA, USA) was utilized (table below summarizes abbreviations of used lectins). Each lectin was diluted to 1:25 and incubated with fixed embryos overnight at room temperature (RT). Embryos were washed in BBT for 2 hr at RT and Vectashield was added. After overnight incubation at 4°C, embryos were mounted on a slide and imaged with a Zeiss Inverted LSM700 Confocal Microscope using a Plan-Apochromat 63X/1.4 Oil Objective. Macrophages in late Stage 11 embryos were imaged at germband entry and evaluated by eye for enriched staining on macrophages compared to other tissues.

**LectinPeanut agglutininUlex**\
**europaeus**\
**agglutininWheat germ**\
**agglutininGriffonia**\
**simplicifolia**\
**agglutinin IMaclura**\
**pomifera agglutininGriffonia simplicifolia**\
**agglutinin II**AbbreviationPNAUEA-IWGAGS-IMPAGS-II**LectinSoybean agglutininDolichos biflorus agglutininConcanavalin AHelix pomatia agglutininLimulus poly-phenus agglutininBauhinia purpurea agglutinin**AbbreviationSBADBAConAHPALPABPA

Macrophage extraction {#s3-7}
---------------------

Embryos were bleached in 50% Chlorox in water for 5 min at RT. Stage late 11/early 12 embryos were lined up and then glued to 50 mm Dish No. 0 Coverslip, 14 mm Glass Diameter, Uncoated dish (Zeiss, Germany). Cells from the germband margin were extracted using a ES Blastocyte Injection Pipet (spiked, 20 μm inner diameter, 55 mm length; BioMedical Instruments, Germany). Extracted cells were placed in Schneider's medium (Gibco, Dublin, Ireland) supplemented with 20% FBS (Sigma-Aldrich, Saint Louis, Missouri, USA).

Immunohistochemistry of extracted macrophages {#s3-8}
---------------------------------------------

Extracted macrophages were collected by centrifugation at 500 g for 5 min at room temperature. The cell pellet was resuspended in a small volume of Phospho-buffered saline (PBS) and smeared on a cover slip. The cell suspension was left to dry before cells were fixed with 4% paraformaldehyde in 0.1M Phosphate Buffer for 20 min at room temperature. Cells were washed 3 times in 0.1M PBS and permeabilized in 0.5% Triton-X 100 in PBS. Cells were blocked for 1 hr at room temperature in 20% Fetal Bovine Serum +0.25% Triton X-100 in PBS. Primary antibodies were diluted in blocking buffer: anti-HA (Roche, Basel, Switzerland) 1:50, anti-Golgin 84, 1:25, anti-Calnexin 99a 1:25, anti-Hrs.8.2 1:25 or anti-Rab7 1:25 all from DSHB ([@bib108]), and incubated for 1 hr at room temperature. Cells were then washed 5 times in blocking buffer. Secondary antibodies were diluted in blocking buffer: anti-rat 633 1:300, anti-mouse 488 1:300 (both from ThermoFisher Scientific, Waltham, Massachusetts, USA). Secondary antibodies were incubated for 1 hr at room temperature. Cells were washed 5 times in PBS + 0.1% Triton X-100 and mounted in VectaShield + DAPI (LifeTechnologies, Carlsbad, USA) utilized at 1:75.

S2 cell work {#s3-9}
------------

S2R+ cells (a gift from Frederico Mauri of the Knoblich laboratory at IMBA, Vienna) were grown in Schneider's medium (Gibco) supplemented with 10% FBS (Gibco) and transfected with PTS1-GFP (a gift from Dr. McNew) and/or the *srpHemo-CG8602::3xmCherry* construct using Effectene Tranfection Reagent (Qiagen, Hilden, Germany) following the manufacturer's protocol. Transfected S2R+ cells were grown on Poly-L-Lysine coated coverslips (ThermoFisher Scientific, Waltham, Massachusetts, USA) in complete Schneider's medium (Gibco) supplemented with 10% FBS (Sigma-Aldrich, Saint Louis, Missouri, USA) and 1% Pen/Strep (Gibco) to a confluency of 60%. To visualize lysosomes, cells were incubated with Lysotracker 75 nM Green DND-26 (Invitrogen) in complete Schneider's medium for 30 min at 25°C. Cells were washed in complete Schneider's medium 3 times before imaging on an inverted LSM-700 (Zeiss). To visualize mitochondria, mitotracker Green FM (Invitrogen, Carlsbad, CA, USA) was diluted in prewarmed Schneider's medium supplemented with 1% Pen/Strep to a concentration of 250 nM. Cells were incubated in the Mitotracker solution for 45 min at 25°C. Cells were then washed 3 times in complete Schneider's medium before imaging.

To visualize Golgi, ER, early and late endosomes as well as the nucleus, S2R+ cells were transfected with MT-CG8602::FLAG::HA (DGRC: FMO06045) or MT-Qsox1::FLAG::HA (DGRC: FMO06379) with Effectene Tranfection Reagent (Qiagen) following the manufacturer's protocol. 24 hr after transfection gene expression was induced by addition of 1 mM Cu2SO4 (Sigma) and cells were incubated for an additional 24 hr. Cells were then fixed in 4% PFA (Sigma) in 0.1M PB for 20 min at room temperature, permeabilized in 0.5% Triton X-100 (Sigma) in PBS for 15 min and blocked for 2 hr in 20% FBS (Sigma), 0.25% Triton X-100 in PBS at room temperature.

Cells were then stained with anti-HA antibody 1:50 (Roche) and either anti-Cnx99a (1:5), anti-Hrs 8.2 (1:5), anti-Golgin 84 (1:5), anti-Rab7 (1:5), anti- GMAP (1:50) or anti- Golgin 245 (1:50) (all antibodies from DSHB) ([@bib108]). Cells were washed in 20% FBS (Sigma), 0.25% Triton X-100 in PBS 5 times and then incubated with anti-rat Alexa Fluor 633 1:50 and either anti-mouse Alexa Fluor 488 or anti-goat Alexa Fluor 488 1:100 (Thermo Fisher) for 2 hr at room temperature. Cells were washed again 5 times and then mounted in Vectashield Mounting Medium +DAPI (Vector Laboratories) and imaged with Zeiss LSM 700 or 800 confocal microscopes. Quantitation of colocalization was performed as indicated below.

The cell line was routinely tested for Mycoplasm infection and found to be negative.

DNA isolation from single flies {#s3-10}
-------------------------------

Single male flies were frozen for at least 3 hr before grinding them in 100 mM Tris-HCl, 100 mM EDTA, 100 mM NaCL and 0.5% SDS. Lysates were incubated at 65°C for 30 min. Then 5M KAc and 6M LiCl were added at a ratio of 1:2.5 and lysates were incubated on ice for 10 min. Lysates were centrifuged for 15 min at 20,000xg, supernatant was isolated and mixed with Isopropanol. Lysates were centrifuged again for 15 min at 20.000xg, supernatant was discarded and the DNA pellet was washed in 70% EtOH and subsequently dissolved in ddH20.

FACS sorting {#s3-11}
------------

Embryos were collected for 1 hr and aged for an additional 5 hr, all at 29°C. Embryos collected from w- flies were processed in parallel and served as a negative control. Embryos were dissociated as described previously ([@bib46]). The cells were sorted using a FACS Aria III (BD) flow cytometer. Emission filters were 600LP, 610/20 and 502 LP, 510/50. Data were analyzed with FlowJo software (Tree Star). The cells from the dissociated negative control *w^-^* embryos were sorted to set a baseline plot.

qPCR {#s3-12}
----

RNA was isolated from approximately 50,000 mCherry positive or mCherry negative FACS sorted macrophages using RNeasy Plus Micro Kit (Qiagen, Hilden, Germany) following manufacturer's protocol. RNA was also isolated from 50 to 100 mg of ovaries (about 15--20 pairs of ovaries extracted as indicated above). Ovaries were homogenized with a pellet homogenizer (VWR, Radnor, USA) and plastic pestles (VWR, Radnor, USA) in 1 ml of Trizol (Thermo Fisher Scientific, Waltham, MA, USA) and centrifuged at 12,000xg for 5 min at 4°C. Further steps were according to the manufacturers protocol. The resulting RNA was used for cDNA synthesis using Sensiscript RT Kit (macrophages) or Omniscript (ovaries) (Qiagen, Hilden, Germany) and oligo dT primers. A Takyon qPCR Kit (Eurogentec, Liege, Belgium) was used to mix qPCR reactions based on the provided protocol. qPCR was run on a LightCycler 480 (Roche, Basel, Switzerland) and data were analyzed in the LightCycler 480 Software and Prism (GraphPad Software). Data are represented as relative expression to a housekeeping gene (2-^Δct^) or fold change in expression (2^-ΔΔct^). Primer sequences utilized for flies were obtained from the FlyPrimerBank (<http://www.flyrnai.org/FlyPrimerBank>). Minerva/CG8602: Fw pr TGTGCTTCGTGGGAGGTTTC, Rv pr GCAGGCAAAGATCAACTGACC. C1GalTA: Fw pr TGCCAACAGTCTGCTAGGAAG, Rv pr CTGTGATGTGCATCGTTCACG. Ugalt: Fw pr GCAAGGATGCCCAGAAGTTTG, Rv pr GATATAGACCAGCGAGGGGAC. RpL32: Fw pr AGCATACAGGCCCAAGATCG, Rv pr TGTTGTCGATACCCTTGGGC

Protein preps from embryos for western blots {#s3-13}
--------------------------------------------

Embryos were collected for 7 hr at 29°C, bleached and hand-picked for the correct stage. 50--200 embryos were smashed in RIPA buffer (150 mM NaCl, 0,5% Sodiumdeoxychalat, 0,1% SDS, 50 mM Tris, pH 8) with Protease inhibitor (Complete Mini, EDTA free, Roche, Basel, Switzerland) using a pellet homogenizer (VWR, Radnor, USA) and plastic pestles (VWR, Radnor, USA) and incubated on ice for 30 min. Afterwards, samples were centrifuged at 4°C, 16,000 g for 30 min and the supernatant was collected and used for experiments. The protein concentration was quantified using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific).

Western blots {#s3-14}
-------------

30 μg of protein samples were loaded on a 4--15% Mini-PROTEAN TGX Precast Protein Gel (Bio-Rad, Hercules, USA) and run at 100V for 80 min in 1x running buffer (25 mM Tris Base, 190 mM glycine and 0.1%SDS) followed by transfer onto Amersham Protran Premium 0.45 μm NC (GE Healthcare Lifescience, Little Chalfont, UK) or Amersham Hybond Low Fluorescence 0.2 μm PVDF (GE Healthcare Lifescience, Little Chalfont, UK) membrane using a wet transfer protocol with 25 mM Tris Base, 190 mM Glycine +20% MeOH at either 100 Volts for 60 min or 200mA for 90 min at Mini Trans-Blot Cell Module (Bio-Rad, Hercules, USA). Membranes were blocked in PBS-T (0.1% Triton X-100 in PBS) containing 2% BSA or Pierce Clear Milk Blocking Buffer (ThermoFisher Scientific) for 1 hr at RT. Primary antibodies were incubated overnight at 4°C at the following concentrations: α-T antigen (Copenhagen) 1:10, α-profilin ([@bib143]), DSHB) 1:50, anti-GFP (clone 2B6, Ogris lab, MFPL), anti-GAPDH (ab181603, Abcam, Cambridge, UK). Afterwards, blots were washed 3x for 5 min in blocking solution and incubated with Goat anti Mouse IgG (H/L):HRP (Bio-Rad, Hercules, USA) or goat-anti-rabbit IgG (H + L)-HRP (Bio-Rad, Hercules, USA) at 1:5 000--10,000 for 1--2 hr at room temperature. Blots were washed 2 × 5 min in blocking solution and 1 × 5 min with PBS-T. Blots were developed using SuperSignal West Femto Maximum Sensitivity Substrate (ThermoFisher Scientific, Waltham, Massachusetts, USA) according to manufacturer's instructions. Chemiluminescent signal was detected using the Amersham Imager 600 (GE Healthcare Lifescience) or VersaDoc (Bio-Rad). Images were processed with ImageJ.

Western blot analysis of S2R+ supernatant {#s3-15}
-----------------------------------------

S2R+ cells were transfected as described previously with srpGal4 UAS-Qsox1::FLAG::HA. 2 days post-transfection, medium was removed and cells were washed with PBS. Afterwards, serum-free S2 medium was added and incubated for approximately 40 hr. Afterwards, supernatant was collected and concentrated using Amicon Ultra-4 10K Centrifugal Filter Device (Merck, [Kenilworth, New Jersey, United States](https://www.google.com/search?client=firefox-b-ab&q=Kenilworth,+New+Jersey&stick=H4sIAAAAAAAAAOPgE-LUz9U3MEkzqChU4gIxjQzMStIstbSyk63084vSE_MyqxJLMvPzUDhWGamJKYWliUUlqUXFAOfEzs9FAAAA&sa=X&ved=2ahUKEwj_q4_HyanfAhWdSxUIHS8mB2EQmxMoATAiegQICBAL)) to gain 80 μl of concentrated supernatant. 20 μl of supernatant was loaded on gel and analyzed by anti-HA (1:200, Roche). Images were processed with ImageJ.

Time-lapse imaging, tracking, speed, persistence and germband entry analysis {#s3-16}
----------------------------------------------------------------------------

Embryos were dechorionated in 50% bleach for 5 min, washed with water, and mounted in halocarbon oil 27 (Sigma-Aldrich, Saint Louis, Missouri, USA) between a coverslip and an oxygen permeable membrane (YSI). The anterior dorsolateral region of the embryo was imaged on an inverted multiphoton microscope (TrimScope II, LaVision) equipped with a W Plan-Apochromat 40X/1.4 oil immersion objective (Olympus). mCherry was imaged at 1100 nm excitation wavelengths, using a Ti-Sapphire femtosecond laser system (Coherent Chameleon Ultra) combined with optical parametric oscillator technology (Coherent Chameleon Compact OPO). Excitation intensity profiles were adjusted to tissue penetration depth and Z-sectioning for imaging was set at 1 µm for tracking and segmentation respectively. For long-term imaging, movies were acquired for 132--277 min with a frame rate of 40 s. All embryos were imaged with a temperature control unit set to 28.5°C.

Images acquired from multiphoton microscopy were initially processed with InSpector software (LaVision Bio Tec) to compile channels from the imaging data, and the exported files were further processed using Imaris software (Bitplane) to visualize the recorded channels in 3D. Macrophage speed and persistence were calculated by using embryos in which the macrophage nuclei were labeled with *srpHemo-H2A::3XmCherry* ([@bib46]). The movie from each imaged embryo was rotated and aligned along the AP axis for tracking analysis. Increasing the gain allowed determination of germband position from the autofluorescence of the yolk. Movies for vnc analysis were analyzed for 2 hr from the time point that cells started to dive into the channels to reach the outer vnc. Macrophage nuclei were extracted using the spot detection function and nuclei positions in xyz-dimensions were determined for each time point and used for further quantitative analysis. Cell speeds and directionalities were calculated in Matlab (The MathWorks Inc., Natick, Massachusetts, USA) from single cell positions in 3D for each time frame measured in Imaris (Bitplane). Instantaneous velocities from single cell trajectories were averaged to obtain a mean instantaneous velocity value over the course of measurement. To calculate directionality values, single cell trajectories were split into segments of equal length (10 frames) and calculated via a sliding window as the ratio of the distance between the macrophage start-to-end location over the entire summed distance covered by the macrophage between successive frames in a segment. Calculated directionality values were averaged over all segments in a single trajectory and all trajectories were averaged to obtain a mean directionality value for the duration of measurement, with 0 being the lowest and one the maximum directionality. T**o** estimate the time for entry into the germband, we increased the gain to visualize the germband position from the autofluorescence of the yolk. We assessed the time point when the first macrophage nucleus reached the edge of the germband (taken as T0) and the time point when the first cell nucleus was just within the germband (taken as T1). T1-T0 was defined as the time for macrophage entry.

Fixed embryo image analysis for T antigen levels {#s3-17}
------------------------------------------------

Embryos were imaged with Plan-Apochromat 63X/1.4 Oil Objective on a Zeiss LSM700 inverted. 10 µm stacks (0.5 µm intervals) were taken for properly staged and oriented embryos, starting 10 µm deep in the tissue. These images were converted into Z-stacks in Fiji. ROIs were drawn around macrophages (signal), copied to tissue close by without macrophages (background) and the average intensity in the green channel of each ROI was measured. For each pair of ROIs background was subtracted from signal individually. The average signal from control ROIs from one imaging day and staining was calculated and all data points from control, mutant and rescue from the same set was divided by this value. This way we introduced an artificial value called Arbitrary Unit (AU) that makes it possible to compare all the data with each other, even if they come from different imaging days when the imaging laser may have a different strength or from different sets of staining. Analysis was done on anonymized samples.

Macrophage cell counting {#s3-18}
------------------------

Transmitted light images of the embryos were used to measure the position of the germband to determine the stages for analysis. The extent of germband retraction away from the anterior along with the presence of segmentation was used to classify embryos. Embryos with germband retraction of between 29--31% were assigned to late Stage 11. Those with 29--41% retraction (early Stage 12) were analyzed for the number of macrophages that had entered the germband and those with 50--75% retraction (late Stage 12) for the number along the ventral nerve cord (vnc), and in the whole embryo. Macrophages were visualized using [confocal microscopy](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/confocal-microscopy) with a Z-resolution of 3 μm and the number of macrophages within the germband or the segments of vnc was calculated in individual slices (and then aggregated) using the Cell Counter plugin in FIJI.

To check that this staging allows embryos from the control and *mrva^3102^* mutant to be from the same time during development, embryos were collected for 30 min and then imaged for a further 10 hr using a Nikon-Eclipse Wide field microscope with a Plan-Apochromat 20X/0.5 DIC water Immersion Objective. Bright field images were taken every 5 min, and the timing of the start of the movies was aligned based on when cellularization occurred. We found no significant difference in when germband retraction begins (269.6 ± 9 min in control and 267.1 ± 3 min in *mrva^3102^,* p=0.75) or in when the germband retracts to 41% (300 ± 9 min for control, 311 ± 5 min in *mrva^3102^*, p=0.23), or in when the germband retraction is complete (386.5 ± 10 min for control, 401.6 ± 8 min for *mrva^3102^,* p=0.75). n = 10 embryos for control and 25 embryos for *mrva^3102^.*

Cloning {#s3-19}
-------

Standard molecular biology methods were used and all constructs were sequenced by Eurofins before injection into flies. Restriction enzymes *BSi*WI, and *Asc*I were obtained from New England Biolabs, Ipswich, Massasuchetts, USA (Frankfurt, Germany). PCR amplifications were performed with GoTaq G2 DNA polymerase (Promega, Madison, USA) using a peqSTAR 2X PCR machine from PEQLAB, (Erlangen, Germany). All Infusion cloning was conducted using an Infusion HD Cloning kit obtained from Clontech's European distributor (see above); relevant oligos were chosen using the Infusion primer Tool at the Clontech website.

### Construction of *srpHemo-minerva* {#s3-19-1}

A 1467 bp fragment containing the Minerva (CG8602) ORF was amplified from the UAS-CG8602:FLAG:HA construct (DGRC) using primers Fw GAAGCTTCTGCAAGGATGGCGCGCGAGGACGAGGAAC, Rv CGGTGCCTAGGCGCGCTATTCAAAGTTCTGATAATTCTCG. The fragment was cloned into the srpHemo plasmid (a gift from Katja Brückner, ([@bib19])) after its linearization with AscI, using an Infusion HD cloning kit.

### Construction of *srpHemo-MFSD1* {#s3-19-2}

A 1765 bp fragment containing the MFSD1 ORF was amplified from cDNA prepared from dendritic cells (a gift from M. Sixt\'s lab) with Fw primer TAGAAGCTTCTGCAACTTTGCTTCCTGCTCCGTTC, Rv primer ATGTGCCTAGGCGCGAAGGAAAGGCTTCATCCGCA). The fragment was cloned into the srpHemo plasmid (a gift from Katja Brückner, ([@bib19]) using an Infusion HD cloning kit (Clontech) after its linearization with AscI (NEB).

### Construction of *srpHemo-mrva::3xmCherry* {#s3-19-3}

Minerva (CG8602) was amplified from a DNA prep from Oregon R flies (Fw primer: AGAGAAGCTTCGTACGCGACAACCCTGCTCTACAGAG; Rv primer CGACCTGCAGCGTACGACCCGATCCTTCAAAGTTCTG). The vector, PCasper4 containing a 3xmCherry construct under the control of the srpHemo promoter ([@bib46]), was digested with BsiWI according to the manufacturer's protocol. The vector and insert were homologously recombined using the In-Fusion HD Cloning Kit.

### Generation of pInducer20-MFSD1-eGFP constructs {#s3-19-4}

For C-terminal tagging MFSD1 was PCR amplified from cDNA prepared from dendritic cells (a gift from M. Sixt lab) (Fw primer:GATCTCGAGATGGAGGACGAGGATG; Rv primer: CGACCGGTAACTCTGGATGAGAGAGC) and digested with XhoI and AgeI (both New England Biolabs, Ipswich, Massasuchetts, USA). This MFSD1 fragment was cloned into XhoI/AgeI digested peGFP-N1 (Addgene, Cambridge, Massachusetts, USA). C-terminally eGFP tagged MFSD1 was further PCR amplified (Fw primer: GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGAGGACGAGGAT; Rv primer: GGGGACCACTTTGTACAAGAAAGCTGGGTATTACTTGTACAGCTC). This fragment was cloned using Gateway BP Clonase II Enzyme mix and Gateway LR Clonase II Enzyme Mix (ThermoFisher Scientific, Waltham, Massachusetts, USA) via donor vector pDonR211 into the final Doxycyclin inducible expression vector pInducer20 ([@bib86]) according to the manufacturer's instructions. pInducer20-MFSD1-eGFP was amplified in stbl3 bacteria (ThermoFisher Scientific, Waltham, Massachusetts, USA).

Precise excision {#s3-20}
----------------

*mrva^3102^* flies which contain the 3102 P element insert in the 5' region of CG8602 were crossed to a line expressing transposase (BL-1429: *pn^1^; ry^503^Dr^1^P\[Δ 2--3\]*). To allow excision of the P Element, males from the F1 generation containing both the P element and the transposase, were crossed to virgins with the genotype Sp/Cyo; PrDr/TM3Ser (gift from Lehmann lab). In the F2 generation white eyed males were picked and singly crossed to Sp/Cyo; PrDr/TM3Ser virgins.

LanA quantification {#s3-21}
-------------------

Images were taken with a Z-resolution of 0.5 μm from the head of late stage 12 embryos using a Zeiss LSM800 confocal microscope and a 40x/1.4 Oil DIC objective. A 4 μm long line was drawn over a macrophage with the middle of the line located approximately at the edge of the cell. mCherry and LanA (488) intensities were measured using the Multichannel Plot Profile Plugin in Fiji. Three lines were drawn on each cell to catch the variability of secretion. Only cells standing alone or in small groups that had at least some small visible amount of extracellular LanA were analyzed. From each embryo, 20 cells were analyzed. Images were anonymized before quantification.

Mammalian cell culture {#s3-22}
----------------------

MC-38 colon carcinoma cells, 4T1 breast carcinoma (ATCC, CRL-2539), Lewis Lung carcinoma LLC1 (ATCC, CRL-1642) and B16-BL6 melanoma (NCI-DTP; B16BL-6) (all gifts from the Borsig lab) were kept in DMEM supplemented with 10% FCS (Sigma-Aldrich, Saint Louis, Missouri, USA), Non-essential Amino Acids, and Na-Pyruvate (Thermo Fisher Scientific, Waltham, Massachusetts, USA). All cells were kept in a humidified incubator at 37°C with 5% CO2. Cells were infected with lentiviral particles containing pInducer20-MFSD1-eGFP. Expression of MFSD1-eGFP was induced with 20 ng/ml (for MC-38) and 100 ng/ml (for 4T1, LLC, B16-BL6) of Doxycycline for 24 hr prior subsequent analysis. Cell lines were routinely tested for Mycoplasm infection and found to be negative. The identity of the cell lines was confirmed by STR analysis by the cell bank from which they were obtained.

Mammalian cell lysis {#s3-23}
--------------------

Cells were lysed in alysis buffer (25 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with a protease inhibitor cocktail (Complete, Roche, Basel, Switzerland) for 20 min on ice, followed by centrifugation at 14,000x g, 4°C for 5 min. The protein lysates were stored at −80°C. Protein concentration was determined with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific).

Mammalian cell immunofluorescence {#s3-24}
---------------------------------

Cells were fixed with 4% formaldehyde (Thermo Fisher Scientific) in PBS for 15 min at room-temperature. Cells were washed three times with PBS followed by blocking and permeabilization with 1% BSA (Sigma-Aldrich, Saint Louis, Missouri, USA)/0.3% Triton X-100 in PBS for 1 hr. Antibodies were diluted in blocking/permeabilization buffer and incubated for 2 hr at room temperature. Primary antibodies used were: anti-GFP (clone 5G4, Ogris lab, MFPL), anti-GRASP65 (Thermo Fisher, PA3-910), anti-Rab5 (Cell Signaling Technology, \#C8B1), anti-Rab7 (Cell Signaling Technology, \#D95F2) and anti-LAMP1 (Abcam, Cambridge, UK, \#ab24170). Cells were washed three times with PBS-Tween20 (0.05%) for 5 min each, followed by secondary antibody incubation in blocking/permeabilization buffer for 1 hr at room-temperature. Secondary antibodies used were: goat anti-mouse IgG (H + L) Alexa Fluor 488 (Thermo Fisher A11001), goat anti-rabbit IgG (H + L) Alexa Fluor 555 (Thermo Fisher, A21428), Cells were counterstained with DAPI (Thermo Fisher) for 10 min in PBS. Cells were mounted with ProLong Gold Antifade Mountant (Thermo Fisher \#P36930). Images were acquired using a Plan-Apochromat 40x/1.4 Oil DIC objective M27 on a Zeiss LSM880 confocal microscope. Pictures were processed with ImageJ.

Quantification of secretory pathway marker colocalization with Mrva, MFSD1 and Qsox1 {#s3-25}
------------------------------------------------------------------------------------

Colocalization analysis was performed by ImageJ's (NIH) Coloc two plugin and determined with the pixel intensity spatial correlation analysis (Pearson's correlation coefficient).

Embryonic protein prep for glycoproteomics {#s3-26}
------------------------------------------

150 mg fly embryos were homogenized in 2 ml 0.1% RapiGest, 50 mM ammonium bicarbonate using a dounce homogenizer. The lysed material was left on ice for 40 min with occasional vortexing followed by probe sonication (5 s sonication, 5 s pause, 6 cycles at 60% amplitude). The lysate was cleared by centrifugation (1,000 × g for 10 min). The cleared lysate was heated at 80°C, 10 min followed by reduction with 5 mM dithiothreitol (DTT) at 60°C, 30 min and alkylation with 10 mM iodoacetamide at room temperature (RT) for 30 min before overnight (ON) digestion at 37°C with 25 µg trypsin (Roche). The tryptic digests were labeled with dimethyl stable isotopes as described ([@bib15]). The digests were acidified with 12 µL trifluoroacetic acid (TFA), 37°C, 20 min and cleared by centrifugation at 10,000 g, 10 min. The cleared acidified digests were loaded onto equilibrated SepPak C18 cartridges (Waters) followed by 3 × CV 0.1% TFA wash. Digests were labeled on the column by adding 5 mL 30 mM NaBH~3~CN and 0.2% formaldehyde (COH~2~) in 50 mM sodium phosphate buffer pH 7.5 (Light, *mrva^3102^*), or 30 mM NaBH~3~CN and 0.2% deuterated formaldehyde (COD~2~) in 50 mM sodium phosphate buffer pH 7.5 (Medium, control). Columns were washed using 3 CV 0.1% FA and eluted with 0.5 mL 50% MeOH in 0.1% FA. The eluates were mixed in a 1:1 ratio, concentrated by evaporation, and resuspended in Jacalin loading buffer (175 mM Tris-HCl, pH 7.4) Glycopeptides were separated from non-glycosylated peptides by Lectin Weak Affinity Chromatography (LWAC) using a 2.8 m column packed in-house with Jacalin-conjugated agarose beads. The column was washed with 10 CVs Jacalin loading buffer (100 µL/min) before elution with Jacalin elution buffer (175 mM Tris- HCl, pH 7.4, 0.8M galactose) 4 CVs, 1 mL fractions. The glycopeptide-containing fractions were purified by in-house packed Stage tips (Empore disk-C18, 3M).

Quantitative O-glycoproteomic strategy {#s3-27}
--------------------------------------

The glycopeptide quantification based on M/L isotope labeled doublet ratios was evaluated to estimate a meaningful cut-off ratio for substantial changes ([@bib114]). The labeled glycopeptides produced doublets with varying ratios of the isotopic ions as well as a significant number of single precursor ions without evidence of ion pairs. Labeled samples from control *srpHemo-3xmCherry* embryos and *mrva^3102^ srpHemo-3xmCherry* mutant embryos were mixed 1:1 and subjected to LWAC glycopeptide enrichment. The distribution of labeled peptides from the LWAC flow-through showed that the quantitated peptide M/L ratios were normally distributed with 99.7% falling within ±0.55 (Log~10~). We selected doublets with less/more than ±0.55(Log~10~) value as candidates for isoform-specific O-glycosylation events.

Mass spectrometry {#s3-28}
-----------------

EASY-nLC 1000 UHPLC (Thermo Scientific) interfaced via nanoSpray Flex ion source to an -Orbitrap Fusion mass spectrometer (Thermo Scientific) was used for the glycoproteomic study. A precursor MS1 scan (m/z 350--1,700) of intact peptides was acquired in the Orbitrap at a nominal resolution setting of 120,000. The five most abundant multiply charged precursor ions in the MS1 spectrum at a minimum MS1 signal threshold of 50,000 were triggered for sequential Orbitrap HCD-MS2 and ETD-MS2 (m/z of 100--2,000). MS2 spectra were acquired at a resolution of 50,000. Activation times were 30 and 200 ms for HCD and ETD fragmentation, respectively; isolation width was four mass units, and one microscan was collected for each spectrum. Automatic gain control targets were 1,000,000 ions for Orbitrap MS1 and 100,000 for MS2 scans. Supplemental activation (20%) of the charge-reduced species was used in the ETD analysis to improve fragmentation. Dynamic exclusion for 60 s was used to prevent repeated analysis of the same components. Polysiloxane ions at *m/z* 445.12003 were used as a lock mass in all runs. The mass spectrometry glycoproteomics data have been deposited to the ProteomeXchange Consortium ([@bib144]) via the PRIDE partner repository with the dataset identifier PXD011045.

Mass spectrometry data analysis {#s3-29}
-------------------------------

Data processing was performed using Proteome Discoverer 1.4 software (Thermo Scientific) using Sequest HT Node as previously described ([@bib114]).

Briefly, all spectra were initially searched with full cleavage specificity, filtered according to the confidence level (medium, low and unassigned) and further searched with the semi-specific enzymatic cleavage. In all cases the precursor mass tolerance was set to six ppm and fragment ion mass tolerance to 20 mmu. Carbamidomethylation on cysteine residues was used as a fixed modification. Methionine oxidation as well as HexNAc and HexHexNAc attachment to serine, threonine and tyrosine were used as variable modifications for MS2 data. All spectra were searched against a concatenated forward/reverse *Drosophila melanogaster*-specific database (UniProt, March 2018, containing 39034 entries with 3494 canonical reviewed entries) using a target false discovery rate (FDR) of 1%. FDR was calculated using target decoy PSM validator node. The resulting list was filtered to include only peptides with glycosylation as a modification. Glycopeptide M/L ratios were determined using dimethyl 2plex method as previously described ([@bib114])

Statistics and repeatability {#s3-30}
----------------------------

Statistical tests as well as the number of embryos/cells assessed are listed in the Figure legends. All statistical analyses were performed using GraphPad Prism and significance was determined using a 95% confidence interval. Data points from individual experiments/embryos were pooled to estimate mean and standard error of the mean. Sample size refers to biological replicates. No statistical method was used to predetermine sample size and the experiments were not randomized. For major questions, data were collected and analyzed masked. Normality was evaluated by D'Agostino and Pearson or Shapiro-Wilk normality test. Unpaired t-test or Mann-Whitney test was used to calculate the significance in differences between two groups and One-Way Anova followed by Tukey post-test or Kruskal-Wallis test followed by Conover or Dunn's post-test for multiple comparisons.

All measurements were performed in 3--38 embryos and at least 37 oocytes. Representative images shown in [Figure 1E--G,I](#fig1){ref-type="fig"}, [Figure 2F,I,](#fig2){ref-type="fig"} [Figure 3A--C](#fig3){ref-type="fig"}, [Figure 5A](#fig5){ref-type="fig"}, [Figure 6B,D and G](#fig5){ref-type="fig"} and [Figure 2---figure supplement 1B-J](#fig2s1){ref-type="fig"}, [Figure 3---figure supplement 1B,H,K](#fig3s1){ref-type="fig"}, [Figure 5---figure supplement 1G, K](#fig5s1){ref-type="fig"} were from separate experiments repeated 3 to 6 times. The stainings underlying [Figure 1---figure supplement 1A-M](#fig1s1){ref-type="fig"}, Figures 2Hand Figure 6-figure supplement 1C-F are from separate experiments that were repeated at least twice. Stills shown in [Figure 3I,L](#fig3){ref-type="fig"} and [Figure 5D](#fig5){ref-type="fig"} are representative images from two-photon movies, which were repeated at least 3 times.
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10.7554/eLife.41801.025

###### Mass spectrometric analysis of the T and Tn antigen containing O-glycoproteome from wild type and *mrva^3102^* mutant Stage 11--12 *Drosophila melanogaster* embryos.

Each row lists an individually identified tryptically processed peptide. The 2^nd^--4^th^ columns describe the analyzed peptide. The 5^th^, 6^th^, 7^th^ and 12^th^ are the names and accessions to Uniprot. The 8^th^ indicates the position of the modified amino acid. The 9^th^ indicates the number and 10^th^ the type of glycosylation. The 11^th^ lists the exact position and the 13^th^ the exact description of glycosylation. The 14^th^ is the ratio of the amount of the particular glycopeptide in the control samples (medium) over the amount in the *mrva^3102^* (light). The 15^th^ is the number of missed cleavages after the tryptic digest. The 16^th^ is the measured intensity. The 17^th^ column shows the mass to charge ratio.

10.7554/eLife.41801.026

###### All candidate proteins from the O-glycoproteome with at least 3-fold changes in T and Tn antigen in the *mrva^3102^* mutant.

Columns list the gene name, the predicted or known function of the gene, if other T or Tn glycosites on the protein are unchanged or changed in the opposite direction, any known human ortholog (identified by BLAST), references for links to cancer and cancer invasion for the mammalian orthologs, the precise site altered, the T and Tn antigen changes observed at a particular glycosylation site, the number of glycosites on the peptide, the peptide sequence and if the glycosylation site is conserved. The site is considered conserved if the human ortholog has a serine or threonine ±5 amino acids from the *Drosophila* glycosite. References: 1 ([@bib42]); 2. ([@bib35]); 3. ([@bib147]); 4. (C.-C. [@bib29]); 5. ([@bib59]); 6. ([@bib84]); 7. ([@bib25]); 8. ([@bib23]) 9. ([@bib146]); 10.([@bib155]); 11. ([@bib80]); 12. ([@bib14]) 13. ([@bib153]); 14. ([@bib43]); 15. ([@bib66]; [@bib65]); 16. ([@bib130]); 17. ([@bib154]); 18. ([@bib58]); 19. ([@bib77]); 20. ([@bib119]); 21. ([@bib120]); 22. ([@bib82]); 23.([@bib149]).

10.7554/eLife.41801.027

###### T or Tn antigen modified receptors from the wild-type St 11--12 *Drosophila melanogaster* embryo O-glycoproteome.

Columns list the gene name for the receptor, its reported function, what kind of glycosylation we identified to be present on the receptors in the wild type sample, and what kind of glycosylation change we observed in the *mrva^3102^* mutant.

10.7554/eLife.41801.028

Data availability {#s6}
=================

Mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD011045.

The following dataset was generated:

ValoskovaKBieblJLarsenISBVakrushevSYClausenHSiekhausDE2019T and Tn antigen glycoproteomics of early St 12 Drosophila embryos, wild type and mrva mutantProteomeXchange ConsortiumPXD011045
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Decision letter

White

Richard M

Reviewing Editor

Memorial Sloan Kettering Cancer Center

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A conserved MFS orchestrates a subset of O-glycosylation to facilitate macrophage dissemination and tissue invasion\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the Siekhaus group use the *Drosophila* system to identify a new regulator of macrophage migration and invasion. They show that macrophages in this system express high levels of T antigen, and that this expression is maintained by an atypical MFS member which they term Minerva. Loss of function studies in the fly demonstrate that Minerva is required for dissemination, and conversely they can rescue this effect by expressing the human ortholog of the gene MFSD1. In addition, they also perform O-glycoprotemics on the flies to identify the range of proteins affected in the mutant, revealing a surprisingly small number of affected proteins. Although the detailed mechanisms by which Minerva acts remain to be elucidated, the reviewers were overall enthusiastic about the quality and importance of the work. We would therefore request revisions as outlined below to further strengthen the paper.

Essential revisions:

1\) Figure 2D. The in situ hybridisations of CG8602 localisation to macrophages are not convincing. These images should be improved or removed. Do the \'invasive\' population of macrophages express higher levels than the non-invasive population that migrate along the vnc?

2\) How specific to macrophages is this? Do other invasive migratory cell types in *Drosophila* require Minerva?

3\) The authors identify Qsox1 as a target of Minerva but what is the role of Qsox1 in driving the invasion of macrophages and how does this fit with what is already known about this invasive migration?

4\) Other than many co-localisation and mutant/RNAi-based data, the study rests to a significant extent on the glycoproteomic data. Here the data were analysed based on various fixed and variable modifications, including HexNAc attachment. However, in the Figure 4 and Supplementary file 1 there is the distinction between T and Tn antigen. Thus, I assume HexHexNAc was also a variable modification (subsection "Mass spectrometry Data analysis"). Was any fragment ion scan performed (e.g., for 204 or 366)? In the supplement, m/z is given as Da: however, daltons refer to mass and not mass/charge ratios -- the charge status is not listed and also not the deconvoluted mass. Thus, in the absence of example figures showing, e.g., MS/MS of Qsox1 O-glycopeptides, the data are difficult to assess. Although deposited in a database, for the sake of easy reference and transparency, example glycoproteomic data should be shown in the paper.

5\) Subsection "T antigen is enriched and required in invading macrophages in *Drosophila* embryos": it is true that Fucα1,2Gal is a known ligand for UEA whether the Gal is 1,3 or 1,4-linked. However, it is an overinterpretation to say that UEA is binding a fucosylated glycan in an insect -- the interaction of lectins with non-mammalian glycomes is understudied due to a lack of relevant glycan arrays. We also do not know whether UEA may bind O-Fuc on a peptide. There is no proof for 1,2-linked Fuc on any *Drosophila* glycan and, other than O-Fuc, no fucose found in an O-glycan of this species. To prove a role for fucose in UEA binding, RNAi of the GDP-fucose transporter or GDP-Fuc synthase or putative FucTs would be needed as done for the T-antigen staining with the core 1 GalT. Therefore, unless the authors have a strategy to explain the UEA binding, it is probably best to rephrase this section, perhaps deleting the sentence "Thus T antigen and a fucosylated structure are upregulated on embryonic macrophages during their invasion" and rephrasing the next sentence to \"as the source of the upregulated signal in embryonic macrophages during invasion and to characterise...\"

10.7554/eLife.41801.032

Author response

> Essential revisions:
>
> 1\) Figure 2D. The in situ hybridisations of CG8602 localisation to macrophages are not convincing. These images should be improved or removed. Do the \'invasive\' population of macrophages express higher levels than the non-invasive population that migrate along the vnc?

We had tried repeatedly to get better *in situs* than the ones in the paper before we submitted it, and have now tried it again with other protocols. However we have not succeeded in this. We therefore have removed our images and will just refer to the excellent BDGP in situs (subsection "An atypical MFS member acts in macrophages to increase T antigen levels", first paragraph). By examining these or our own in situs we do not see any difference in the levels of expression of CG8602 in invading macrophages versus those on the ventral nerve cord, and have included this information. To assess this with precise quantitation would require us to be able to differentially label the two different populations, sort them, and then conduct qPCR on them. We are unable to do this as we have no specific markers or drivers for these different subsets at the moment. We can extract a few macrophages with a pipette from particular areas but not enough for such analysis.

We have observed for several of the genes that we study that although their RNA is expressed in all macrophages before invasion, their phenotype only obviously affects the few that migrate into the germband. We hypothesize that this permits flexibility as to which macrophages make their way in.

> 2\) How specific to macrophages is this? Do other invasive migratory cell types in Drosophila require Minerva?

The main other cell type known to carry out invasive migration in *Drosophila* are the border cells, which move in the ovary from their initial location in the surrounding epithelium between the nurse cells to make their way to their final location at the edge of the oocyte (PMID 12511865). This tissue invasion is mediated by Cadherin rather than Integrin based adhesion (PMID 9971747, 24855950). Germ cells also move through a narrow region, as they emerge from the midgut through gaps in the epithelium produced by ingressing midgut cells (PMID 22619387). They are thought to move in an amoeboid, minimally adhesive migratory mode (PMID 15469969). We have examined both border cell and germ cell migration in the control and *mrva^EP3102^*mutant and find no evidence for a defect in the *mrva* mutant. We have included this data in Figure 3---figure supplement 1H-L and in the subsection "Minerva is not required for border cell invasion or germ cell migration".

> 3\) The authors identify Qsox1 as a target of Minerva but what is the role of Qsox1 in driving the invasion of macrophages and how does this fit with what is already known about this invasive migration?

To completely define the role Qsox1 plays in aiding macrophage invasion would require at least one more paper's worth of work. To begin to shed some light on this question within the eight week target, we pursued three approaches: 1) Characterizing the *qsox1* mutant phenotype in greater detail through live imaging, 2) Examining where in the cell Qsox1 is localized, 3) Testing a potential effect on an ECM component. These data are shown in two new figures, Figure 5 and Figure 5---figure supplement 1, which also incorporates the data on Qsox1 that was already in the previous version of the paper in the former figure panels Figure 4I-J and Supplementary Figure 4D-F.

1\) We would have loved to examine the phenotype of Qsox1 mutated (S/T to A) at the amino acids whose T antigen modification is dependent on Minerva. However these flies are still under construction. We therefore conducted 2-photon imaging of the *qsox1* P element mutant and examined the effect on invasion (Figure 5---video 5, stills in Figure 5D). We observed that Qsox1 is required for entry into the germband (Figure 5F), with macrophages in the *qsox1* mutant pausing twice as long (49 minutes in the mutant vs. 22 minutes in the control) before entering. We have also added a figure panel showing this data for the *mrva* mutant (Figure 3K, in which entry takes on average 102 minutes). We also see a decrease in the speed of initial dissemination in the head (Figure 5E) in the *qsox1* mutant with again a similar but not as strong effect as in the *mrva* mutant (Figure 3J).

2\) We find that Qsox1 when expressed in S2R+ cells localizes to the Golgi, endosomes and can be secreted (Figure 5H-I, Figure 5---figure supplement 1G-J), indicating a potential for extracellular functions. We also observe colocalization with Mrva.

3\) Guided by the literature which has shown a role for Qsox1 in vertebrates in the extracellular deposition and anchoring of Laminin into the ECM (PMID 23704371), we examined the localization of Laminin A (LanA) and observed higher levels inside macrophages in *mrva* and *qsox1* mutant embryos and somewhat higher levels adjacent but not directly next to the macrophage cell edge (Figure 5J, Figure 5---figure supplement 1K-N). These data are consistent with a role for Qsox1 in speeding the secretion of LanA, and potentially allowing its deposition and anchoring in the ECM.

We describe these results in the subsection "Minerva raises T antigen levels on proteins required for invasion", and discuss them in the subsection "An invasion program regulated by Minerva" in the context of a model integrating other data in which Qsox1 dependent-integration of normal levels of LanA into the ECM is required to allow macrophages to anchor themselves and exert traction forces that speed initial tissue invasion.

> 4\) Other than many co-localisation and mutant/RNAi-based data, the study rests to a significant extent on the glycoproteomic data. Here the data were analysed based on various fixed and variable modifications, including HexNAc attachment. However, in the Figure 4 and Supplementary file 1 there is the distinction between T and Tn antigen. Thus, I assume HexHexNAc was also a variable modification (subsection "Mass spectrometry Data analysis").

You are correct, and we have amended the Materials and methods to state this. Thank you for noticing this. "Methionine oxidation as well as HexNAc and HexHexNAc attachment to serine, threonine and tyrosine were used as variable modifications for MS2 data."

> Was any fragment ion scan performed (e.g., for 204 or 366)?

No additional fragment ion scans were performed. As is written in the Materials and methods section (see below), all precursors were fragmented with both ETD and HCD fragmentation:

"The five most abundant multiply charged precursor ions in the MS1 spectrum at a minimum MS1 signal threshold of 50,000 were triggered for sequential Orbitrap HCD-MS2 and ETD-MS2 (m/z of 100--2,000).\"

> In the supplement, m/z is given as Da: however, daltons refer to mass and not mass/charge ratios -- the charge status is not listed and also not the deconvoluted mass.

We thank the reviewers for catching this error, which arose due to the default assignment by the Proteome Discoverer software (Thermo). We have now replaced Da with \"Th\" on column Q in Supplementary file 1, the column which corresponds to the precursor ions' m/z. A few additional parameters such as charge, charge deconvoluted mass (M+H^+^), δ m/z (ppm) and Xcorr were added as well.

> Thus, in the absence of example figures showing, e.g., MS/MS of Qsox1 O-glycopeptides, the data are difficult to assess. Although deposited in a database, for the sake of easy reference and transparency, example glycoproteomic data should be shown in the paper.

We have now added the MS/MS traces for the Qsox1 O-glycopeptides to the paper in Figure 4I and Figure 4---figure supplement 1B-C.

> 5\) Subsection "T antigen is enriched and required in invading macrophages in Drosophila embryos": it is true that Fucα1,2Gal is a known ligand for UEA whether the Gal is 1,3 or 1,4-linked. However, it is an overinterpretation to say that UEA is binding a fucosylated glycan in an insect -- the interaction of lectins with non-mammalian glycomes is understudied due to a lack of relevant glycan arrays. We also do not know whether UEA may bind O-Fuc on a peptide. There is no proof for 1,2-linked Fuc on any Drosophila glycan and, other than O-Fuc, no fucose found in an O-glycan of this species. To prove a role for fucose in UEA binding, RNAi of the GDP-fucose transporter or GDP-Fuc synthase or putative FucTs would be needed as done for the T-antigen staining with the core 1 GalT. Therefore, unless the authors have a strategy to explain the UEA binding, it is probably best to rephrase this section, perhaps deleting the sentence "Thus T antigen and a fucosylated structure are upregulated on embryonic macrophages during their invasion" and rephrasing the next sentence to \"as the source of the upregulated signal in embryonic macrophages during invasion and to characterise...\"

We expressed the VDRC RNAi line 30238 against the fucose transporter Efr but did not see any reduction in UEA binding. We did not have time to grow a large enough stock of flies to be able to conduct qPCR analysis on the FACS sorted macrophages from the RNAi expressing embryos to determine if the knockdown was effective and thus to see if we could conclude that UEA does not recognize fucosylated glycan structures in the insect. We have therefore changed the text in the paragraph as suggested by the reviewers.

[^1]: Department of Biochemistry, The University of Lausanne, Epalinges, Switzerland.

[^2]: These authors contributed equally to this work.
